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Executive Summary 44 
WHO estimates that nearly one million people become infected every day with any of four 45 
curable sexually transmitted infections (STIs; chlamydia, gonorrhoea, syphilis, 46 
trichomoniasis). Despite their high global incidence, STIs remain a neglected area of research. 47 
In this Commission we have prioritised five areas that represent particular challenges in STI 48 
treatment and control. Chlamydia remains the most commonly diagnosed bacterial STI in 49 
high income countries despite widespread testing recommendations, sensitive and specific 50 
non-invasive testing techniques and cheap effective therapy. We discuss the challenges for 51 
chlamydia control and evidence to support a shift from the current focus on infection-based 52 
screening to improved management of diagnosed cases and of chlamydial morbidity such as 53 
pelvic inflammatory disease. The emergence and spread of antimicrobial resistance in 54 
Neisseria gonorrhoeae is globally recognised. We review current and potential future control 55 
and treatment strategies, including novel antimicrobials. Bacterial vaginosis (BV) is the most 56 
common vaginal disorder in women, yet current treatments are associated with high rates of 57 
recurrence. This might relate to evidence that suggests sexual transmission is integral to the 58 
pathogenesis of BV, which has significant implications for the development of effective 59 
management approaches. STIs disproportionately affect low and middle income settings. We 60 
review strategies for case management, focusing on point-of-care tests that hold considerable 61 
potential for improving STI control. Lastly, STIs in men who have sex with men (MSM) have 62 
increased since the late 1990s. We discuss the contribution of new biomedical HIV prevention 63 
strategies and risk compensation. Overall this Commission aims to enhance our understanding 64 
of some of the key challenges facing us in the field, and outlines new approaches to improve 65 
the clinical management of STIs and public health. 66 
  67 
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Introduction 68 
Sexually transmitted infections (STIs) are amongst the most common acute conditions 69 
worldwide.
1
 The World Health Organization (WHO) estimated that there were 357 million 70 
new cases of four common curable STIs; trichomoniasis (143 million cases), chlamydia (131 71 
million), gonorrhoea (78 million), and syphilis (5.6 million) globally in 2012 (Figure 1).
2
 In 72 
addition, there are alarming increases in antimicrobial resistance (AMR) in Neisseria 73 
gonorrhoeae and Mycoplasma genitalium.
3 
Although most STIs are not usually fatal, they 74 
result in a significant burden of disease.
1
 The complications of curable STIs include pelvic 75 
inflammatory disease (PID), ectopic pregnancy, infertility, chronic pelvic pain, seronegative 76 
arthropathy, neurological and cardiovascular disease;
4
 STIs in pregnancy can cause foetal or 77 
neonatal death, premature delivery, neonatal encephalitis, eye infections and pneumonia;
4
 and 78 
STIs increase the infectiousness of and susceptibility to HIV.
5
 Despite this burden, STIs 79 
remain a neglected field for clinical and public health practice and for research.
6
 People with 80 
STIs experience stigma, STIs disproportionately affect marginalised groups such as sex 81 
workers and men who have sex with men (MSM) and condemnatory moral attitudes towards 82 
STIs result in unwillingness to prioritise STI control policies.
6-8
 In this Commission of Lancet 83 
Infectious Diseases, we have selected five key issues for STI control that face major 84 
challenges globally and for which action is imperative.  85 
This Commission addresses current challenges for research, practice and policy that we 86 
selected because they are common, are important global health priorities, or because new 87 
evidence is emerging in the area. Of necessity, this Commission has excluded important 88 
subjects. M. genitalium was not included, despite the rapid emergence of resistance to both 89 
first and second line treatments, but M. genitalium AMR and clinical management options 90 
have been recently reviewed elsewhere.
3,9
 We also omitted herpes simplex virus, for which 91 
vaccine development is progressing rapidly,
10
 human papillomavirus (HPV), for which 92 
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vaccination is highly effective,
11
 but for which implementation is now the key challenge, and 93 
Trichomonas vaginalis infections because there are no new strategies for treatment or control. 94 
Partner notification is an essential part of the management of most STIs and is mentioned in 95 
several parts of the Commission. We use the term to include all processes involved in 96 
informing the sex partners or needle-sharing contacts of persons with STIs of their potential 97 
exposure to an infectious disease and ensuring their evaluation and/or treatment.
4
 We consider 98 
partner management, partner services and partner information to be synonymous.     99 
Part 1 of the Commission addresses Chlamydia trachomatis, commonly known as 100 
chlamydia. Chlamydia is the most common bacterial STI globally
1
 and causes serious 101 
reproductive tract complications in women.
12
 Yet, 20 years after the first randomised 102 
controlled clinical trial (RCT) of an intervention to reduce its complications,
13
 we remain 103 
unsure how to reduce its prevalence and impact on society. Indeed, the most recent RCT of a 104 
screening intervention did not find a marked effect on prevalence despite a substantial 105 
increase in the proportion of the target population that received screening.
14
 Hocking and Low 106 
assess the latest research about screening, treatment and management of chlamydia and 107 
suggest a way forward to define chlamydia control priorities for the future.   108 
In Part 2 of the Commission, Unemo addresses the globally recognised threat of the 109 
emergence and spread of AMR in N. gonorrhoeae. This organism has become resistant to 110 
virtually all antibiotics that have been used to treat it since sulphonamides were first used in 111 
the 1930s. The first clinical failure using dual therapy with ceftriaxone and azithromycin was 112 
verified in 2015.
15
 For this reason, we focus on current and future treatment strategies, 113 
including three novel antimicrobials that are being evaluated in phase 2 or 3 RCTs. We also 114 
report on novel strategies that aim to reduce the incidence and prevalence of gonorrhoea in 115 
MSM, which should also reduce the probability of AMR developing. Ultimately, the 116 
development of vaccines against both N. gonorrhoeae and C. trachomatis are likely to be the 117 
only sustainable solutions to control these infections.
10
  118 
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The Commission chose to include bacterial vaginosis (BV) for three main reasons, even 119 
though it is not considered a traditional STI. First, an accumulating body of epidemiological 120 
and microbiological evidence suggests that sexual transmission is integral to its 121 
pathogenesis.
16,17
 Second, BV has been neglected, although it is the most prevalent urogenital 122 
disorder amongst women of reproductive age worldwide and is associated with serious 123 
reproductive and obstetric sequelae, including preterm delivery and increased risk of STI and 124 
HIV acquisition and HIV transmission.
18,19 
Third, treatment failure rates are unacceptably 125 
high; more than half of women have a recurrence after recommended therapy but neither BV 126 
treatment efficacy nor outcomes have improved for decades.
20
 In Part 3 of the Commission, 127 
Bradshaw and colleagues summarise the research implicating sexual transmission and 128 
propose combination approaches to management that include antimicrobials, biofilm-129 
disrupting agents and partner treatment.
 
   130 
Part 4 of the Commission addresses STIs in low and middle income settings where more 131 
than 90% of curable STIs and almost all of the global burden of STIs occur. Francis and 132 
colleagues review key strategies for STI case management and control, including syndromic 133 
management, presumptive periodic treatment and partner notification. But they focus on rapid 134 
diagnostic tests and point of care (POC) tests within a published framework; being affordable, 135 
sensitive, specific, user-friendly, rapid and robust, equipment-free and delivered to end-users 136 
(ASSURED).
21
 POC tests have considerable implications for STI control in high-income 137 
settings too, but their potential benefits are greatest in resource constrained settings where 138 
healthcare infrastructure is most limited.  139 
Part 5 of the Commission discusses epidemics of STIs in MSM in high income settings in 140 
the context of three biomedical treatment strategies that use antiretroviral therapies (ART) to 141 
prevent HIV infection. Two strategies are prophylactic treatments to reduce susceptibility in 142 
HIV-uninfected individuals: post-exposure prophylaxis (PEP) given after specific high risk 143 
exposures and pre-exposure prophylaxis (PrEP), given to HIV-uninfected individuals for 144 
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continuous periods of high risk exposure to prevent acquisition of HIV. The third strategy, 145 
known as treatment as prevention (TasP), reduces HIV infectiousness and involves starting 146 
ART as soon as HIV infection is diagnosed to prevent transmission to uninfected partners. 147 
These interventions have all been suggested to increase risky sexual behaviours through risk 148 
compensation and to result in increased transmission of STIs.
22
 de Vries and colleagues 149 
review the evidence linking PEP, TasP and PrEP strategies to risk compensation and 150 
increasing STI rates.  151 
The Commission ends with a ‘call to action’, in which we ask policy makers to rise to the 152 
public health challenge of effective STI control. Our call includes a broad suite of approaches 153 
that are often shared across infections or risk groups. They involve the optimisation of: 154 
surveillance for behaviours, infections and AMR; access to health services, early diagnosis, 155 
appropriate treatment and partner notification, and also intensified research into: rapid POC 156 
tests to detect both STIs and AMR; novel antimicrobials and/or treatment approaches; and the 157 
understanding of STI transmission or pathogenesis.    158 
 159 
Part 1. Chlamydia control – what should we do? 160 
Twenty years after the publication of the first RCT of an intervention to reduce the incidence 161 
of PID by screening for asymptomatic chlamydia infection in young women,
13
 we still need to 162 
ask, “what should we do?” about chlamydia control. Three linked factors make this an 163 
important question. First, C. trachomatis remains the most commonly diagnosed bacterial 164 
STI, despite chlamydia testing recommendations that have been in place for years in several 165 
high income countries.
23-27
 Second, whilst infection might be asymptomatic in over 80% of 166 
cases,
28,29
 chlamydia can cause tissue damage, particularly in the female reproductive tract 167 
where ascending infection can cause PID, which contributes to chronic pelvic pain, ectopic 168 
pregnancy and tubal factor infertility (Figure 2).
12
 Third, technological advances make 169 
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chlamydia diagnosis ever easier (if not cheaper): nucleic acid amplification tests (NAATs) 170 
using self-collected specimens, online test kits, mobile phones for receiving results and rapid 171 
tests.
30
 However, the diagnosis of PID still relies on insensitive and non-specific clinical 172 
signs.
27
  173 
Chlamydia control requires “a broad range of deliberate sustained activities that aim to 174 
reduce the incidence and prevalence of chlamydia and the incidence of reproductive tract 175 
complications”.31 The general definition of infectious disease control involves agreement on 176 
locally acceptable levels,
32
 and makes a distinction between the infection and the disease(s) 177 
that it causes. But an acceptable level of genital chlamydia infection or chlamydia-associated 178 
PID, ectopic pregnancy or tubal factor infertility has not been defined in any setting. The 179 
range of chlamydia control activities is broad (Figure 3) and countries should have a 180 
chlamydia control strategy that defines primary and secondary prevention activities and 181 
systems for monitoring and evaluation.
31 
Secondary prevention starts with case detection and 182 
management to prevent complications; case management includes history-taking and clinical 183 
examination, diagnostic tests, treatment, partner notifications, health promotion advice, 184 
follow-ups and surveillance.
31
 Over time, particularly in high income countries, discussions 185 
about chlamydia control have come to focus more on screening for asymptomatic infections 186 
in young sexually active adults, rather than clinical case management of infection or PID.  187 
The WHO Global Health Sector Strategy on STIs 2016-2021 states that, “because best 188 
strategies to control and measure chlamydia infections are still to be defined, further research 189 
and cost-effectiveness analyses are to be encouraged”(p17).33 With this in mind, in this 190 
section of the Commission we first outline the global epidemiology of genital chlamydia and 191 
its complications. We review evidence about current chlamydia control activities and the 192 
effects of screening interventions on chlamydia prevalence and PID. We then discuss the 193 
challenges ahead for chlamydia control and question whether we should shift from an 194 
infection-based focus on screening uptake to a health outcomes-based focus with improved 195 
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case management and investment in research to further our understanding about the 196 
epidemiology of PID and other chlamydia associated morbidity.   197 
 198 
Global epidemiology of chlamydia infections  199 
WHO estimated that, in 2012, about 131 million people worldwide became newly infected 200 
with chlamydia (Figure 1) and that 4·2% of women and 2·7% of men aged 15 to 49 years had 201 
a prevalent infection.
2
 In high income countries, chlamydia is most common in young 202 
heterosexual adults aged ≤26 years with estimates from meta-analysis of population-based 203 
surveys of 4·3% (95% confidence interval (CI) 3·6 to 5·0%) in women and 3·6% (95% CI 2·8 204 
to 4·4%) in men.
34
 Chlamydia is also common among MSM attending sexual health clinics 205 
amongst whom chlamydia positivity ranges from 2% to 5% for urethral infection and 6% to 206 
9% for rectal infection.
35-37
 Few countries have nationally representative surveys of chlamydia 207 
prevalence (i.e. random samples of the general population aimed at providing unbiased 208 
estimates) but, amongst those that do,
38-44
 prevalence is similar in women and men aged ≤26 209 
years, and appears similar in countries that promote widespread chlamydia testing (e.g. USA 210 
and England)
44,45 
and those without recommendations (e.g. Croatia and Slovenia) (Figure 211 
4).
40,46 
Within countries, higher chlamydia prevalence is associated with social disadvantage
47
 212 
and is higher in people from minority ethnic groups.
43,48
  213 
In low and middle income countries, population-based surveys of chlamydia prevalence 214 
are also very uncommon.
49-52
 Estimates of chlamydia prevalence in the general population in 215 
the few countries that have conducted such surveys are mostly similar to those in high income 216 
countries (Figure 4).
2
 The lowest estimate was in women in India (<1%)
50
 and the highest in 217 
Papua New Guinea, which estimated a prevalence of 45% among women ≤26 years.51 Data 218 
from unselected 15 to 24 year old women attending antenatal clinics in South Pacific Islands 219 
also find that around 20% of pregnant women have chlamydia.
53,54
 Whilst we found no 220 
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nationally representative surveys in South Africa, chlamydia prevalence amongst pregnant 221 
women was as high
55
 as that found in the South Pacific Islands. Reasons for regional 222 
variations have not been examined in detail. In addition to study design issues, social, cultural 223 
and economic conditions, differences in sexual practices, gender inequality and circumcision 224 
practices might play a role.
2,53,56
   225 
 226 
Global epidemiology of PID and reproductive tract morbidity  227 
Compared with international data about chlamydia infection, very little is known about 228 
international variations in the incidence and prevalence of PID and other reproductive tract 229 
morbidity caused by chlamydia. WHO estimated that chlamydial infections caused a total of 230 
1·43 million disability-adjusted life years (DALYs) in 2012, most in low and middle income 231 
countries (36% African Region, 25% South East Asia Region).
57
  232 
The rate of hospitalisation for PID from any cause varies from around 37 to 194 per 233 
100,000 women aged 15-39 years in different countries.
58
 Chlamydia infection is found in 234 
association with about 20% of PID cases; one study at a large sexual health clinic in Australia 235 
found no causative organism in over 60% of PID cases.
59
 A major challenge is the lack of 236 
consensus about criteria for the diagnosis of upper genital tract chlamydial disease and the 237 
lack of non-invasive tests including new radiological imaging. PID is usually diagnosed based 238 
on lower abdominal and cervical signs and symptoms and diagnostic criteria lack sensitivity 239 
and specificity.
27 
240 
 241 
Natural history of Chlamydia trachomatis  and reproductive complications 242 
The host immune response to chlamydia strongly influences susceptibility, clearance, the 243 
probability of upper genital tract pathogenesis and, ultimately, the effectiveness of 244 
11 
 
interventions.
60,61
 Untreated infection that resolves spontaneously might confer some 245 
immunity against further infection,
62
 but the duration of immunity is unclear. Antimicrobial 246 
treatment, on the other hand, might reduce the immune response and once treated, people 247 
become susceptible to infection again, increasing their risk of repeat chlamydia infection, the 248 
“arrested immunity hypothesis”.63,64 Repeat chlamydia infections after treatment are common; 249 
in cohort studies, over 20% of young women enrolled from general practice acquired a repeat 250 
infection within 12 months of treatment.
65,66
 251 
Several reviews have examined the risk of sequelae following infection,
12,67-70
 but 252 
estimates are limited by diagnostic challenges. Mathematical syntheses of evidence from 253 
different types of studies estimate that the probability of clinical PID following infection with 254 
chlamydia is about 16% (95% credible interval 6% to 25%)
71
 and the probability of tubal 255 
factor infertility in women who have ever had a chlamydia infection is about 1% (varies 256 
depending on age).
72
 These models also estimate that the proportion of PID, ectopic 257 
pregnancy and tubal factor infertility attributable to chlamydia is 20%, 5% and 29% to 45%, 258 
respectively.
73
 The risk of reproductive tract morbidity in women might increase with 259 
repeated infection.
74-76 
It is unclear, however, whether the increase in risk is due to an increase 260 
in the cumulative infection time or a higher probability of progression with each subsequent 261 
infection.
12
 Ascertainment bias in diagnosis might also explain the observations if physicians 262 
are more likely to test for chlamydia in previously infected women who attend with lower 263 
abdominal pain, or to assign the diagnosis of PID to a woman diagnosed with chlamydia.  264 
We do not know how or when chlamydia ascends to the upper genital tract, but there are 265 
two key hypotheses.
61
 The cellular paradigm assumes that actively infected epithelial cells 266 
play the key role and that chemokines secreted by these cells damage the tissues directly. The 267 
immunological paradigm assumes that tissue damage occurs due to T cell responses involved 268 
in clearing infection after repeat or persistent infection. If the cellular paradigm is the main 269 
driver of chlamydia pathogenesis, then identifying and treating infections before they ascend 270 
12 
 
should be the main focus of control programmes. If the immunological paradigm is more 271 
important, then prevention of repeat infections should be prioritised.
60 
272 
The timing of ascending infection will also affect the impact of a screening intervention. If 273 
chlamydia ascends the canal shortly after infection causing immediate tubal inflammation, 274 
annual screening and treatment will not stop tubal pathology.
77
 A mathematical model
78
 using 275 
data from a RCT,
79
 found that the trial results of the effect of a single chlamydia screen on the 276 
cumulative incidence of PID up to one year later, could only be achieved if progression to 277 
PID occurred at a constant rate or at the end of infection.  278 
Pregnant women infected with chlamydia have an increased risk of pre-term delivery
80
 and 279 
vaginally-delivered babies of untreated mothers are at risk of conjunctivitis and pneumonia.
81
 280 
Among men, chlamydia can cause epididymo-orchitis,
82
 but effects on male fertility are 281 
disputed; some have found no effect, some suggest decreased semen quality, or impaired 282 
sperm fertilisation capacity and DNA integrity.
83,84 
283 
 284 
Current chlamydia control activities 285 
Case detection and management are central to chlamydia control strategy in addition to 286 
primary prevention of STIs. Clinical guidelines can include recommendations for 287 
opportunistic chlamydia testing to detect asymptomatic infection in people with specified risk 288 
factors for infection (Figure 3). Opportunistic testing can also be implemented at a population 289 
level as a screening programme. Screening programmes require infrastructure not only for 290 
chlamydia testing, but for treatment, partner notification, repeat testing, monitoring and 291 
quality control.
31
 Several high income countries including Australia, Canada, England and the 292 
USA recommend yearly opportunistic chlamydia screening for all sexually active women or 293 
both women and men in the age groups at highest risk of infection.
23-27
 The coverage of 294 
chlamydia testing has been used to monitor performance,
85-87
 but none of these countries sets 295 
targets for chlamydia prevalence or PID incidence.   296 
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Surveys in Europe show that the number of countries with any chlamydia control activities 297 
increased between 2007 and 2012.
26
 The number of countries reporting the use of chlamydia 298 
case management guidelines and opportunistic testing increased but fewer countries reported 299 
that they had an ongoing or planned chlamydia screening programme.
26
 Of note, the 300 
Netherlands and Ireland have elected not to implement screening programmes and Sweden 301 
and Denmark, both of which have had widespread opportunistic chlamydia screening, 302 
reported that their STI control strategies have partly shifted from promoting testing to 303 
intensifying primary prevention activities.
26
 Ongoing debate about the evidence to support 304 
chlamydia screening
88-90
 and its cost effectiveness
88
 might have influenced these decisions.  305 
 306 
Effectiveness of chlamydia screening in clinical trials 307 
The rationale for chlamydia screening is that testing should detect asymptomatic infections in 308 
women before they cause PID or other reproductive complications; if a large enough 309 
proportion of the population can be screened, reduced incidence and prevalence of infection 310 
ought to further prevent reproductive complications indirectly by reducing exposure to 311 
infection.
91
  312 
A systematic review of chlamydia screening interventions
89
 found four RCTs that looked 313 
at the effects on PID incidence after a single offer of a chlamydia screening test.
13,79,92,93
 314 
Overall, the trial results suggest that PID incidence was lower in intervention than control 315 
groups (summary risk ratio, RR 0·68, 95% CI 0·49 to 0·94, I
2
 8%).
89
 However, when 316 
stratified by risk of bias, the summary effect was smaller in the two trials at low risk of bias 317 
(RR 0·80, 95% CI 0·55 to 1·17)
79,92
 than in those at high or unclear risk of bias (RR 0·42, 318 
95% CI 0·22 to 0·83),
13,93
 suggesting the overall result might overestimate the protective 319 
effects of a screening test. Another completed cluster RCT will report on the association of up 320 
to four rounds of chlamydia testing on the incidence of PID measured in hospitals and 321 
primary care clinics.
94
  322 
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Two cluster RCTs have looked at the effects of repeated rounds of chlamydia testing 323 
targeting 16 to 29 year old men and women in the general population.
14,95
 Neither trial found a 324 
reduction in estimated prevalence. The trial in the Netherlands invited people each year by 325 
post (register-based screening) and the trial in Australia offered opportunistic testing in 326 
general practice. Chlamydia test uptake was <20% in both trials, even with individual patient 327 
reminders (Netherlands) or further support for clinicians (Australia). In Peru, a cluster RCT 328 
among female sex workers found that after four years of a multifaceted intervention, 329 
estimated prevalence was 28% lower in women in the intervention areas (RR 0·72, 95% CI 330 
0·54 to 0·98).
96
  331 
Only one trial reported on the impact of screening on ectopic pregnancy, female infertility 332 
and epididymitis in men. The intervention involved a single offer of screening, uptake was 333 
low and outcomes did not differ between intervention and control groups.
92
 No RCT to date 334 
has reported the effects of an intervention that offers chlamydia screening during pregnancy 335 
on pregnancy or neonatal outcomes. One RCT in the USA that compared antibiotic treatment 336 
with placebo in women with chlamydia detected at 23 to 29 weeks of gestation, found no 337 
reduction in low birth weight, preterm birth or neonatal death in intention to treat analysis.
97
 338 
One cluster RCT in Uganda of presumptive antibiotic treatment found reductions in low birth 339 
weight, neonatal death and ophthalmia neonatorum; the antibiotic regimen, azithromycin, 340 
cefixime and metronidazole covered several genital tract infections other than chlamydia.
98
 341 
A review of cost-effectiveness studies found that chlamydia screening might be cost-342 
effective at nationally accepted thresholds of cost per quality adjusted life year in certain 343 
circumstances in high income countries.
88
 Incremental cost-effectiveness ratios are sensitive 344 
to assumptions about the epidemiology and natural history of chlamydia including the 345 
probability of developing sequelae, screening uptake, the type of model used, assumptions 346 
about quality of life and the cost of management of the sequelae.
88,99
   347 
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 348 
Effects of chlamydia control from observational data 349 
Whilst RCTs provide data about the efficacy of chlamydia screening interventions under 350 
research conditions, surveillance, ad hoc surveys and routine data are used to monitor the 351 
performance of STI control strategies over time. These sources of data provide valuable 352 
information but need to be interpreted carefully, taking into account selection, measurement, 353 
ecological and response biases.  354 
Chlamydia incidence and prevalence  355 
There are no data available to monitor population-based chlamydia incidence over time. In 356 
Great Britain and the USA, population-based chlamydia prevalence surveys have been 357 
repeated during the time when chlamydia testing rates have increased. In Great Britain, two 358 
surveys ten years apart found similar estimates among women and men aged 18 to 24 years in 359 
2010-2011 (women, 3·2%, 95% CI 2·2 to 4·6%; men, 2·6%, 95% CI 1·7 to 4·0%) and in 360 
1999-2000 (women, 3·1%, 95% CI 1·8 to 5·2%; men, 2·9%, 95% CI 1·3 to 6·3%);
44
 361 
chlamydia test coverage increased from about 8% per year in 2008
100
 to about 30% in 362 
2011.
101
 In the USA, chlamydia prevalence in women aged 15-24 years was 4·1% (95% CI 363 
2·4 to 6·8%) in 1999–2000 and 3·8% (2·4 to 6·0%) in 2007–2008 with fluctuations in the 364 
years between;
43
 chlamydia testing coverage among 16 to 24 year old women was reported to 365 
be >35% per year.
85,102,103
 More intensive chlamydia screening in a small cohort of adolescent 366 
women in Indiana, USA did not reduce prevalence.
104
 The women were tested every three 367 
months and treated if they had a positive chlamydia test result; at each interval around 10% of 368 
women tested were chlamydia test positive.
104
  369 
Several factors might help explain why the estimated chlamydia prevalence in the general 370 
population does not appear to have declined during a period of increasing chlamydia testing. 371 
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First, the size of chlamydia prevalence surveys limits statistical precision and modest 372 
reductions cannot be ruled out. Second, chlamydia test uptake might not have been 373 
sufficiently high for long enough; mathematical modelling studies show that any level of a 374 
hypothetical chlamydia screening intervention will reduce prevalence over time, but that 375 
coverage of around 35% per year or more would be needed to achieve substantial reductions 376 
within a ten-year period.
105,106
 Third, suboptimal case management with low levels of partner 377 
notification, antimicrobial treatment failure and an increasing incidence of repeated infection 378 
following antimicrobial treatment for chlamydia might sustain levels of prevalent infections. 379 
Fourth, it is possible that testing and treatment is reducing levels of immunity against 380 
chlamydia in the population leading to increased susceptibility to infection.
64
 Fifth, auto-381 
inoculation in women of cervical chlamydia infection from the rectal site has been suggested 382 
as a factor that could contribute to repeated detection of chlamydia in genital samples;
107
 383 
reports of rectal chlamydial infection in women have increased.
108,109
 Finally, persistent forms 384 
of C. trachomatis might contribute to sustained prevalence. Chlamydia under the selective 385 
pressure of beta-lactam antibiotics,
110
 interferon-gamma (IFN-Ƴ) or deprivation of nutrients 386 
such as iron and amino acids, can enter a persistent, metabolically inactive state
111,112
 where 387 
they are viable but semi-refractory to treatment.
110,113,114   
388 
PID and other reproductive tract complications  389 
Routine data about diagnoses on discharge from hospital have shown declining trends in PID 390 
and ectopic pregnancy during periods of increasing chlamydia testing and increasing 391 
chlamydia diagnosis rates in several countries.
115-121
 Ecological associations between 392 
chlamydia testing and PID need careful interpretation.
60
 Comparisons across larger numbers 393 
of countries and longer time periods show that the degree to which chlamydia control efforts 394 
account for the declining trend in PID incidence is not so clear. The Organisation for 395 
Economic Cooperation and Development (OECD) collates hospital discharge by diagnostic 396 
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categories for its member countries.
122 
Figure 5 shows data for “inflammatory diseases of 397 
female pelvic organs”, which includes PID from any cause (supplement table 1). There are 398 
limitations in comparing the absolute rates between countries because of differences in how 399 
the conditions are diagnosed, investigated and coded. However, trends over time show a 400 
general decrease in the rate of discharge from hospital for inflammatory diseases of the pelvis 401 
over the last two decades in countries that have very different levels of chlamydia control 402 
activity. For example, in Belgium, Ireland and Slovenia, countries with little chlamydia 403 
testing,
26
 hospitalisations have dropped by about 30% over the past 15 years. In countries with 404 
data from the early 1990s, the biggest declines in hospitalisations coincide with sudden sexual 405 
behaviour changes and with falls in the rates of other STIs, which are attributed to responses 406 
to the HIV pandemic.
22,90,123
 A cross-country analysis that compared PID, ectopic pregnancy 407 
and infertility hospitalisation data
58
 also found similar trends in high chlamydia testing 408 
countries (Denmark, New Zealand, Sweden)
26,124
 and low testing countries (Australia, 409 
Netherlands, Switzerland)
26,125
 from 1999 to 2008. Whilst inpatient admissions for these 410 
conditions have become less common, in countries that collect data from ambulatory and 411 
primary care settings, PID diagnoses have also fallen. 412 
 413 
Future challenges for the control of chlamydia 414 
Shift of focus from monitoring test uptake to measuring PID incidence  415 
To date, chlamydia control strategies in several high income countries promote screening for 416 
asymptomatic infection with a focus on monitoring chlamydia test uptake and chlamydia 417 
prevalence. It is surprising therefore, that limited attention has been given to monitoring PID 418 
incidence and its complications given that prevention of PID and its associated complications 419 
is a key goal of chlamydia control. There has also been limited attention on research to further 420 
our understanding of the natural history and immunopathology of C. trachomatis infection 421 
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including the development of non-invasive measures of clinical and subclinical tubal 422 
infection, inflammatory and damage and biomarkers to predict upper genital tract pathology.
60
 423 
We urgently need investment in research to further our understanding of chlamydia natural 424 
history and develop non-invasive tools to detect upper genital tract disease and to establish 425 
surveillance systems to record and monitor trends in PID and other chlamydia related 426 
complications over time.  427 
 428 
Realistic targets for chlamydia prevalence and incidence should be established  429 
Strategies for chlamydia control should be appropriate to levels of chlamydia prevalence and 430 
incidence in the general population and key populations such as pregnant women, sex workers 431 
and MSM. In countries with longstanding case detection activities, including opportunistic 432 
testing and screening (mostly high income countries), it is conceivable that chlamydia 433 
prevalence has reached an equilibrium and that further investments to increase the overall 434 
coverage of chlamydia testing might not achieve additional gains in reducing the burden of 435 
infection in the population. Within these countries, however, chlamydia control efforts should 436 
focus on reducing social and ethnic inequalities in rates of chlamydia and PID, improving 437 
health outcomes through better case management of those diagnosed with chlamydia and 438 
establishing surveillance systems to more reliably and accurately monitor PID, ectopic 439 
pregnancy and infertility incidence in both primary care, ambulatory and hospital settings.  440 
In low and middle income countries efforts should be directed towards strengthening 441 
primary prevention and case management for people presenting with symptomatic chlamydia 442 
infection (see Part 4), as well as research to better define the prevalence of infection and 443 
burden of chlamydial disease. In a limited number of countries, such the South Pacific 444 
Islands, chlamydia prevalence in the general population appears to be very high. Here, 445 
intensive research is needed to understand the reasons for high chlamydia prevalence and to 446 
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plan for evidence-based sustainable interventions. Mass drug administration of azithromycin 447 
for trachoma control has been associated with a reduction in the prevalence of genital 448 
chlamydia.
126
 Given the high probability of re-infection, possible increase in susceptibility to 449 
PID after treatment, and selection pressure for antimicrobial resistance (AMR), mass 450 
treatment should not be introduced to control genital chlamydia infections in the absence of a 451 
sustainable comprehensive chlamydia control strategy and health service infrastructure. 452 
Nevertheless, in all countries, there are opportunities to improve case management of 453 
diagnosed cases to reduce the risk of chlamydia associated complications.   454 
 455 
Improved case management 456 
Use of the most efficacious antimicrobial treatment: AMR has not been detected in C. 457 
trachomatis, but the widespread use of single dose azithromycin for uncomplicated chlamydia 458 
infections is being questioned.
127-130
 Two meta-analyses comparing a single 1 g azithromycin 459 
with seven days of doxycycline (100 mg twice per day) found that azithromycin efficacy was 460 
slightly lower for urogenital chlamydia (94% versus 97%)
131
 and substantially lower for rectal 461 
chlamydia infection (83% versus 99%).
132
 For men, the efficacy of azithromycin for both 462 
urogenital and rectal infection was below the WHO threshold of 95% recommended for a first 463 
line treatment.
133
 Furthermore, the widespread use of single dose azithromycin to treat 464 
chlamydial infections is likely to have contributed to macrolide resistance in Treponema 465 
pallidum, N. gonorrhoeae (see Part 2)
134-136
 and M. genitalium.
137
  466 
 467 
Partner notification: Partner notification has been recommended as a part of most STI 468 
management strategies, including syndromic management (see Part 4), to help interrupt 469 
transmission of infections, prevent potential re-infection, and prevent complications. 470 
Improvements in partner notification are vital for chlamydia control. In addition to preventing 471 
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re-infection and halting ongoing transmission, testing and treating sexual partners of people 472 
with chlamydia is efficient for case finding because they are likely to also be infected.
138
 473 
From a health economic perspective, doubling the efficacy of partner notification (from 0·4 to 474 
0·8 partners per index case) would cost less than increasing the screening coverage of men to 475 
the same level as women.
139
 Expedited partner therapy (EPT) and accelerated partner therapy 476 
(APT) are partner notification approaches that allow partners to receive treatment without a 477 
face-to-face consultation in a health-service setting. A Cochrane review has found that EPT 478 
was more successful than simple patient referral in reducing repeat infection in patients with 479 
gonorrhoea and chlamydia.
138
 APT, its equivalent in the UK, is acceptable to healthcare 480 
providers and patients
140
 and an RCT is underway to evaluate its effectiveness in reducing 481 
repeated infection. Further work is needed to resolve medico-legal issues that limit wider 482 
implementation of these partner notification approaches
141
 and to ensure that opportunities to 483 
test for HIV and other STIs are not missed.
139 
484 
 485 
Re-testing to detect repeat chlamydia infections early: There is no evidence from RCTs that 486 
repeated testing for chlamydia after treatment has an impact on reducing chlamydia 487 
transmission in the population, but re-testing can detect repeat infections early. Guidelines 488 
about re-testing intervals vary between countries: some countries recommend a test of cure 489 
within three to six weeks after diagnosis,
26
 others recommend testing to find repeated 490 
infections within three to six months.
26,27,142,143
 A mathematical modelling study suggests that 491 
an interval of two to five months after treatment optimises the detection of repeat infection.
144
 492 
Mailed specimen collection kits and mobile phone text messages are effective interventions 493 
for increasing re-testing uptake and their impact on reducing chlamydia transmission and PID 494 
should be evaluated.
145,146 
495 
 496 
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Rapid and POC tests 497 
Rapid diagnostic tests and POC tests allow diagnosis and treatment decisions to be made at 498 
the same visit, reducing time to treatment and losses to follow up.
147,148 
The status of POC 499 
tests for chlamydia and other STIs is discussed in Part 4. 500 
 501 
Chlamydia vaccine  502 
In all countries, an effective vaccine would overcome many of the problems of chlamydia 503 
control. While the profile of a chlamydia vaccine remains to be determined, prioritising high 504 
levels of immunity against infection or limited protection against infection but strong 505 
protection against upper genital tract disease,
149
 the prospects for a chlamydia vaccine are 506 
now considered promising.
150
 WHO and the US National Institutes of Health have developed 507 
a STI vaccine roadmap that identifies priority actions for chlamydia vaccine development.
150
 508 
Several candidate chlamydia vaccines could enter Phase 1 clinical trials in the next few 509 
years.
10 
510 
 511 
Conclusion 512 
Over the last 20 years, awareness about chlamydia as a common STI worldwide has 513 
increased.
2,33
 Over the same period, research to increase knowledge about the natural history 514 
of chlamydia or its disease burden has not kept up, even though the first RCT of a chlamydia 515 
control intervention was primarily focused on the prevention of PID.
13
 The focus of 516 
chlamydia control efforts in high income countries has been on increased coverage of testing 517 
for asymptomatic chlamydia infection, whilst fewer advances have been made in research to 518 
improve primary prevention and case management. Chlamydia control priorities could be set, 519 
in future, based on infectious disease principles, to define acceptable levels of chlamydia 520 
prevalence and incidence and disease that match the epidemiology in different geographical 521 
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regions and within different population groups. Priorities for improving case management 522 
include effective partner notification strategies and re-testing to detect repeat infections early 523 
and reduce the risk of chlamydia association complications. Surveillance systems could 524 
improve to record and monitor trends in PID and other chlamydia related complications over 525 
time. The investment and research agendas called for by international experts
60,150,151
 to 526 
further our understanding about the natural history of chlamydia and develop non-invasive 527 
measures to predict upper genital tract disease should be implemented.  528 
 529 
Part 2. Gonorrhoea – inevitable antimicrobial resistance – current and 530 
future treatment options? 531 
Of the 78 million estimated new gonorrhoea cases among adults globally in 2012, the highest 532 
number was in the WHO Western Pacific Region (35.2 million, Figure 1). Accordingly, the 533 
vast majority of the gonorrhoea burden globally is in low and middle income countries.
2
 534 
There is no vaccine against N. gonorrhoeae so effective, accessible and inexpensive 535 
antimicrobial treatment is an essential part of gonorrhoea control measures together with 536 
primary prevention, diagnostics, partner notification and epidemiological surveillance. If N. 537 
gonorrhoeae infections become untreatable, the numbers of people that experience 538 
complications of infection, such as PID, ectopic pregnancy and infertility, and the facilitation 539 
of HIV transmission and acquisition, will substantially increase.
2,152-154
 N. gonorrhoeae has 540 
developed antimicrobial resistance (AMR) to all drugs previously or currently recommended 541 
for treatment. This section of the present Commission reviews and discusses the emergence 542 
and spread of AMR in N. gonorrhoeae, current and future treatment options, with a focus on 543 
novel antimicrobials, and additional actions to control gonorrhoea and AMR in N. 544 
gonorrhoeae. 
 
545 
23 
 
 546 
Emergence and spread of AMR in N. gonorrhoeae 547 
Since the first antimicrobials, sulphonamides, were introduced for the treatment of gonorrhoea 548 
in the mid-1930s gonococci have repeatedly shown an extraordinary ability to develop 549 
resistance to all antimicrobials that have been introduced, using almost all known AMR 550 
mechanisms.
153 
The hypothesis is that, in modern times, AMR in gonococci has usually 551 
developed first in the WHO Western Pacific Region (frequently Japan) followed by 552 
international spread.
153,155,156
 For many infectious diseases including gonorrhoea, overuse and 553 
misuse (including unrestricted access, suboptimal quality and dosing) of antimicrobials has 554 
resulted in AMR in bacterial species that share their AMR determinants through horizontal 555 
gene transfer and subsequent recombination. Horizontal gene transfer is particularly likely in 556 
the pharynx, which harbours many non-gonococcal Neisseria species, and can facilitate the 557 
emergence and spread of AMR
157
 particularly in high-frequency populations such as MSM 558 
and commercial sex workers.
 
Inadequate monitoring of in vitro AMR, 559 
pharmacokinetics/pharmacodynamics, and clinical efficacy of antimicrobials facilitate both 560 
the initial emergence of AMR and the subsequent spread of resistant strains, particularly in 561 
settings with a high incidence of gonorrhoea and ineffective control measures.
152,153,155,156,158
 562 
It is crucial to improve the understanding of the dynamics and drivers of the emergence of 563 
AMR as well as transmission of gonococcal strains and their AMR, which can provide an 564 
enhanced rationale for antimicrobial stewardship and management. Whole-genome 565 
sequencing and other new molecular technologies will be invaluable to elucidate the evolution 566 
and transmission of gonococcal strains and their AMR, locally, nationally and 567 
internationally.
159  
568 
Many countries already have high prevalence rates of gonococcal resistance to all 569 
antimicrobials that have been used for treatment, including sulphonamides, penicillins, 570 
tetracyclines, fluoroquinolones and early generation macrolides and cephalosporins.
152-154,158
 571 
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The prevalence of multidrug-resistant (MDR)
155
 gonococcal strains significantly increased 572 
during the last decade.
152-154,158 
Resistance to extended-spectrum cephalosporins (ESCs), the 573 
last remaining options for empiric first-line monotherapy, has also been detected in many 574 
countries. The first extensively drug-resistant (XDR)
155
 gonococcal strains, displaying high-575 
level resistance to ceftriaxone (minimum inhibitory concentration (MIC)s 2-4 mg/L) and 576 
retained resistance to previously used therapeutic antimicrobials, have also been verified in 577 
Japan, France and Spain.
160-162
 Fortunately, these “superbugs” have not spread further, 578 
suggesting significantly decreased biological fitness. Some additional ceftriaxone-resistant 579 
strains isolated in Japan and Australia during recent years have also been studied in detail,
163-
580 
165
 showing that both ceftriaxone-resistant strains and ceftriaxone resistance-determining 581 
penicillin-binding protein 2 (PBP2) segments (lethal target for ESCs) are spreading.
165
 582 
Additional sporadic gonococcal strains with low-level ceftriaxone resistance have been 583 
described internationally.
158,166
 Importantly, strains with non-mosaic PBP2s can also develop 584 
ceftriaxone resistance, as described particularly in Asia, e.g. China, Korea, and Vietnam, but 585 
also in Argentina.
158,166
 Many additional ceftriaxone-resistant strains might already be 586 
circulating but are undetected due to the suboptimal AMR surveillance in many settings. 587 
Ceftriaxone or dual antimicrobial therapy (mainly ceftriaxone 250-500 mg×1 plus 588 
azithromycin 1-2 g×1) are currently the only options for empirical first-line therapy in most 589 
countries.
158,167-172  
590 
 
591 
Current treatment of gonorrhoea 592 
Principles and definitions used in conventional antimicrobial treatment 593 
Empirical therapy is treatment given at the first health care visit before any laboratory results 594 
are available, following recommendations in evidence-based treatment guidelines. The ideal 595 
characteristics of a first-line therapy are that it: has high efficacy (cures >95% of urogenital 596 
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and extragenital infections), includes multiple targets (to increase activity and delay resistance 597 
development), has no or minimal cross-resistance with other antimicrobials, is showing slow 598 
selection/induction of resistance determinants in N. gonorrhoeae, has different mechanisms of 599 
action for drugs included in dual therapy, is available as a single oral dose, with a fixed-dose 600 
combination (FDC) for dual oral therapy, is widely available and affordable in appropriate 601 
quality and dose, has an appropriate paediatric formulation (e.g. suspension or syrup), is 602 
stable (at high temperature and humidity levels), has no or minimal drug-drug interactions, is 603 
safe (including during pregnancy and lactation), is well tolerated, and is also active against 604 
concurrent C. trachomatis and M. genitalium infections (make it useful in syndromic 605 
management).  606 
Treatment guidelines should be informed by up-to-date, local and quality-assured 607 
AMR surveillance data. AMR can emerge quickly and patterns vary geographically so large 608 
RCTs are rarely conducted. Changes in recommended treatments are mostly based on 609 
laboratory-based AMR surveillance data (the point estimate of tested strains should show that 610 
≥95% are susceptible), rather than clinical surveillance of cure rates.  Alternative criteria for 611 
changing a recommended first-line therapy have been suggested, for example that the lower 612 
95% CI rather than the point estimate should be ≥95%, or that >99% or >97% of strains from 613 
high-frequency transmitting populations should be susceptible.
173-175
 Ideally, additional 614 
factors should also be taken into consideration, including prevalence, local epidemiology, 615 
diagnostics used, transmission frequency, partner notification and management strategies, 616 
treatment strategies (strategies used and antimicrobials available), and cost-effectiveness, 617 
should be considered.
153,158,176 
 618 
 619 
Antimicrobial monotherapy  620 
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Cefixime 400 mg×1 orally and especially ceftriaxone 125-1000 mg×1 intramuscularly (IM) or 621 
intravenously (IV) have been the last options for empirical first-line monotherapy in many 622 
countries.
152-156,158,170
 Unfortunately, treatment failures with cefixime have been verified in 623 
many countries worldwide, and rare failures following treatment of pharyngeal gonorrhoea 624 
with ceftriaxone (250-1000 mg×1) have also been verified in several countries.
156,158
 Verified 625 
ceftriaxone treatment failures are probably the tip of the iceberg because few countries 626 
conduct active surveillance and confirm treatment failures according to international 627 
recommendations.  628 
To avoid treatment failures, increased doses of ceftriaxone (1 g×1 IM/IV) have been used 629 
in some countries.
177-180 
Based on the dosages administered for community-acquired 630 
pneumonia, up to 2 g×1 of ceftriaxone would likely be tolerated. Increased doses of 631 
ceftriaxone are probably only a short-term solution based on current knowledge of gonococcal 632 
AMR emergence, ESC MICs of gonococcal “superbugs” and other ESC-resistant strains, 633 
verified ESC treatment failures and ESC pharmacokinetic/pharmacodynamic simulations. For 634 
example, 20-24 hours of free ESC above MIC (fT>MIC) can be required for effective treatment 635 
with ESCs.
181
 According to Monte Carlo simulations, reflecting the diversity inherent within 636 
patient populations, of ceftriaxone 1 g×1, sufficient fT>MIC (20-24 hours) might not be 637 
achieved in up to 5% of patients even for gonococcal strains with ceftriaxone MICs as low as 638 
0·125 mg/L, which are relatively common in many countries. The median fT>MIC is 639 
therefore 40·3 hours but the lower 95% CI of fT>MIC (19·6 hours) is below the required 20-640 
24 hours.
181 
These findings might overestimate the number of treatment failures because few 641 
failures have been identified, but they show the wide circulation of gonococcal strains that 642 
could cause ceftriaxone treatment failures. 
  
643 
 644 
Dual antimicrobial therapy  645 
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Several agencies and countries recommend dual antimicrobial therapy for empirical first-line 646 
gonorrhoea treatment in response to emerging ESC resistance, including WHO (global 647 
recommendations), Europe, Germany, United Kingdom, Australia, USA, and Canada.
27,167-172 
648 
To summarise, all these guidelines, except those of WHO
172
 and Canada,
171
 recommend only 649 
ceftriaxone plus azithromycin as first-line for uncomplicated anogenital gonorrhoea in adults. 650 
There are no RCTs that provide optimal doses of ceftriaxone and azithromycin for currently 651 
circulating gonococcal strains and recommendations vary: ceftriaxone doses range from 250 652 
mg×1 IM (WHO, USA and Canada) to 1 g×1 IM (Germany); and doses of azithromycin range 653 
from 1 g×1 orally (WHO, USA, Canada, UK and Australia) to 2 g×1 orally (Europe).
27,167-172
 654 
WHO
172
 and Canadian
171
 guidelines additionally recommend an oral first-line dual therapy, 655 
cefixime 400 mg×1 (WHO) or 800 mg×1 (Canada) plus azithromycin 1 g×1.
171,172
 656 
Pharmacodynamic studies have shown that cefixime 800 mg (especially 400 mg×2, given 6 657 
hours apart) increases the cefixime fT>MIC compared to 400 mg×1.
181
 In most countries, 658 
however, only cefixime 400 mg×1 is licensed because gastrointestinal adverse events are 659 
more common with 800 mg×1.
182
 Many clinical failures have been verified with cefixime 400 660 
mg×1,
156,158 
but also with cefixime 800 mg×1.
182
 Finally, WHO also recommends 661 
monotherapy with ceftriaxone 250 mg×1, cefixime 400 mg×1, or spectinomycin 2 g×1, but 662 
only if up-to-date, local, high-quality AMR surveillance data support their use.
172
 Owing to 663 
low cure rates, spectinomycin monotherapy should only be used if pharyngeal gonorrhoea has 664 
been excluded; otherwise, azithromycin should also be given.
152
 
 
665 
The recommendations for dual therapy with ceftriaxone plus azithromycin are not based on 666 
evidence from RCTs. The selection of these antimicrobials and their doses has been based on 667 
AMR surveillance data, predicted AMR trends, old clinical trials, case reports of clinical 668 
failures with ESCs,
156,158
 pharmacokinetic/pharmacodynamic simulations,
181
 and expert 669 
opinion.
170
 Unfortunately, these recommended antimicrobials might not protect each other 670 
from the development of resistance.
183
 However, in practice the combination of ceftriaxone 671 
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and azithromycin appears to cure almost all gonorrhoea cases, concomitant resistance to 672 
ceftriaxone and azithromycin is exceedingly rare and consequently the spread of any emerged 673 
ceftriaxone resistance appears to have been mitigated so far. In addition, dual therapy 674 
eradicates concurrent C. trachomatis and many M. genitalium infections. However, 675 
susceptibility to ceftriaxone is decreasing and azithromycin resistance is increasing in many 676 
settings internationally, and concomitant resistance to both antimicrobials has 677 
emerged.
152,153,158
 Gonococcal strains with high-level azithromycin resistance (MIC≥256 678 
mg/L) have been isolated in several countries worldwide and an outbreak of such strains is 679 
ongoing in the UK.
134,158 
All the recommended and alternative dual antimicrobial regimens 680 
include azithromycin 1-2 g×1 and due to the azithromycin resistance, in practice many 681 
gonorrhoea cases will be administered ceftriaxone monotherapy. Furthermore, the first global 682 
treatment failure with dual therapy (ceftriaxone 500 mg×1 IM plus azithromycin 1 g×1 683 
orally), due to a ceftriaxone- and azithromycin-resistant gonococcal XDR strain, was recently 684 
verified in the UK.
15
 The higher cost and inconvenience of dual therapy also render it less 685 
suitable for low and middle income countries, where also high-quality ceftriaxone can be 686 
lacking, which will limit the mitigation of emergence and spread of gonococcal AMR 687 
globally. 688 
 
689 
Future treatment of gonorrhoea 690 
Improved dual antimicrobial therapy  691 
Dual antimicrobial therapy
27,167-172
 is recommended for treatment where up-to-date, local, and 692 
high-quality AMR surveillance data do not support other therapy. Ideally, owing to the rapid 693 
emergence of azithromycin resistance in N. gonorrhoeae (and also additional STIs such as M. 694 
genitalium infections), at least as a temporary solution azithromycin could be replaced by 695 
solithromycin if the ongoing Phase 3 RCT provides evidence of effectiveness, tolerability and 696 
29 
 
safety. Furthermore, susceptibility to spectinomycin is exceedingly high 697 
globally,
152,153,158,170,172 
and it would be valuable to have this drug widely available again. 698 
There are concerns that spectinomycin resistance would be rapidly selected if it was more 699 
frequently used but it has been used in Korea for decades (52%-73% of treatments in 2009-700 
2012) and no resistant isolates have been found since 1993.
184
 Nevertheless, spectinomycin 701 
only eradicates a proportion of pharyngeal gonorrhoea (52%)
185
 and should, ideally, be used 702 
in a dual therapy combination, e.g. with solithromycin, which might protect it from resistance 703 
development. 704 
Novel accessible and cost-effective antimicrobials are essential. Ideally, these should be 705 
used in new dual therapies, to preserve their effectiveness, and, if there are oral preparations, 706 
in FDCs that increase activity and adherence and mitigate resistance development. One RCT 707 
has evaluated two novel dual regimens, gentamicin (240 mg×1 IM) plus azithromycin (2 g×1 708 
orally), and gemifloxacin (320 mg×1 orally) plus azithromycin (2 g×1 orally), for the 709 
treatment of uncomplicated urogenital gonorrhoea in men and women.
186
 Gentamicin plus 710 
azithromycin cured 100% of cases (202/202) and gemifloxacin plus azithromycin 99·5% of 711 
cases (198/199). No serious adverse events occurred, but mild-moderate gastrointestinal 712 
adverse events such as nausea and diarrhoea were frequent. Of concern, 3·3% and 7·7% of 713 
patients, respectively, vomited within one hour and might have lost a substantial amount of 714 
the drugs.
186
 Consequently, these two regimens should mainly be considered for treatment of 715 
ceftriaxone-resistant cases, treatment failures with recommended regimen, or ESC allergy.   716 
 717 
Repurposing old antimicrobials  718 
Old antimicrobials, such as gentamicin, ertapenem, and fosfomycin, have been suggested for 719 
future therapy. Several shortcomings with these antimicrobials have been previously 720 
reviewed. Briefly, clinical data are lacking (ertapenem) or old, incomplete, mainly low-721 
quality, and only from limited geographic areas, patient populations (only males), and 722 
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anatomical sites (only urogenital); <95% cure rate; appropriate 723 
pharmacokinetic/pharmacodynamic parameters for gonorrhoea, relationship between MIC 724 
and treatment outcome, and resistance breakpoints are lacking.
152,153,156,158,176,187-189 
These 725 
limitations preclude their widespread use as empirical monotherapies, but particularly in new 726 
dual antimicrobial regimens they might be useful in case of ceftriaxone resistance or ESC 727 
allergy. A multi-centre (n=8) non-inferiority Phase 3 RCT, aiming to enrol 718 participants, 728 
evaluating gentamicin 240 mg×1 IM plus azithromycin 1 g×1 orally for treatment of 729 
uncomplicated anogenital and pharyngeal gonorrhoea is ongoing 730 
(www.research.uhb.nhs.uk/gtog); the comparator is ceftriaxone 500 mg×1 IM plus 731 
azithromycin 1 g×1 orally. Finally, using timely molecular prediction of resistance to 732 
ciprofloxacin, based on targeting gyrA mutation(s), this old antimicrobial can be used as 733 
personalised treatment for patients in whom ciprofloxacin susceptibility has been 734 
confirmed.190-193   735 
 736 
New antimicrobials with only in vitro data available 737 
Several new antimicrobials (derivates of earlier developed antimicrobials or new 738 
antimicrobial classes) have proven relatively potent in vitro activity against gonococcal 739 
strains, but clinical data are lacking. These antimicrobials include the fluoroquinolones 740 
avarofloxacin (JNJ-Q2), delafloxacin (RX-3341), sitafloxacin (DU-6859), and WQ-3810; 741 
bicyclic macrolides (bicyclolides) modithromycin (EDP-420/EP-013420/S-013420) and EDP-742 
322; tetracyclines eravacycline (TP-434) and tigecycline (fluorocycline and glycylcycline, 743 
respectively); 2-acyl carbapenems SM-295291 and SM-369926; aminomethyl 744 
spectinomycin;
194
 lipoglycopeptide dalbavancin, pleuromutilin lefamulin (BC-3781), boron-745 
containing inhibitor AN3365, LpxC inhibitors, FabI inhibitor e.g. MUT056399, tricyclic 746 
topoisomerase inhibitor REDX05931 (evaluated also in mice),
195,196 
and topoisomerase II 747 
inhibitor VXc-486 (VT12-008911), which all have been recently reviewed.
152,153,156,158,176,194-
748 
31 
 
196
 A Phase 3 RCT designed to evaluate delafloxacin (2×450 mg×1 orally) compared to 749 
ceftriaxone (250 mg×1 IM) for treatment of uncomplicated gonorrhoea was recently 750 
terminated (http://clinicaltrials.gov/show/NCT02015637).  751 
 752 
Novel antimicrobials in clinical trial evaluation  753 
Solithromycin (CEM-101), zoliflodacin (AZD0914/ETX0914), and gepotidacin 754 
(GSK2140944) are novel orally administered antimicrobials in clinical evaluation for 755 
treatment of gonorrhoea.
197-217
 The main characteristics of these antimicrobials are 756 
summarised in table 1. 757 
Solithromycin: The first fluoroketolide solithromycin is structurally similar to the ketolide 758 
telithromycin but it is less toxic and has increased stability and activity.
202,208,212 
759 
Solithromycin, like other macrolides and ketolides, inhibits protein synthesis, but 760 
solithromycin has three bacterial 23S rRNA binding sites that increase the activity and delay 761 
development of resistance.
208
 Solithromycin has proven a high in vitro activity against 762 
geographically, temporally and genetically diverse wild type, MDR and XDR international 763 
gonococcal reference strains and clinical isolates, with in vitro and clinical resistance to all 764 
currently and previously recommended antimicrobials.
202,212
 No major cross-resistance with 765 
other antimicrobials has been observed, but strains with high-level azithromycin resistance 766 
(MIC≥256 mg/L) can be resistant to solithromycin (MICs=4-32 mg/L).202  767 
Administering a single solithromycin dose (50-1600 mg) to healthy adults, the time-to-768 
peak concentration (Tmax) was 1·5-6 hours and the plasma half-life (T1/2) 3·2-7·4 hours.
214
 A 769 
Phase 1 study evaluating pharmacokinetic properties, safety and tolerability of a 1 g oral dose 770 
within plasma, vaginal, cervical, seminal, rectal, and pharyngeal samples is ongoing 771 
(https://clinicaltrials.gov/ct2/show/NCT02348424).  772 
A Phase 2 clinical trial evaluating the efficacy of solithromycin 1 g×1 or 1·2 g×1 orally in 773 
the treatment of males and females with uncomplicated urogenital gonorrhoea was performed 774 
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(https://clinicaltrials.gov/ct2/show/NCT01591447).
203 
Forty-six patients received 775 
solithromycin and were evaluable for microbiological cure (1 g×1 (n=22) and 1·2 g×1 776 
(n=24)). All (100%) were subsequently culture negative at all sites examined. Solithromycin 777 
additionally cured 82% of C. trachomatis infections (n=11) and 70% of M. genitalium 778 
infections (n=10). The adverse effects were dose-dependent and giving 1 g×1 the most 779 
prevalent were mild diarrhoea (42%), nausea (26%), and fatigue/asthenia (10%). However, 780 
most nausea and vomiting (3%) appeared ≥1 hour after ingestion and the drug was likely 781 
already absorbed.
203
 Additional data are needed and, to further increase gastrointestinal 782 
tolerability, an extended-release formulation of solithromycin might be valuable. 783 
Solithromycin (1 g×1 orally) is currently in a Phase 3 non-inferiority RCT for treatment of 784 
uncomplicated urogenital gonorrhoea in males and females (SOLITAIRE-U; 785 
https://clinicaltrials.gov/ct2/show/NCT02210325), evaluating efficacy, tolerability and safety 786 
(table 1). Of concern, analysing the data from the initial patient cohort of 262 patients 787 
solithromycin demonstrated high success rates of 80·5 percent in the microbiological intent to 788 
treat population but only 91·3 percent in the microbiologically evaluable population (100% 789 
success rate for females). Consequently, solithromycin did not demonstrate non-inferiority to 790 
standard of care treatment. No N. gonorrhoeae isolates demonstrated solithromycin resistance 791 
at baseline or test-of-cure. Thus, the solithromycin treatment failures were most likely related 792 
to the duration of solithromycin exposure at the site of infection and adjustments to the dosing 793 
regimen (and/or possibly formulation), without substantially increasing the dose-dependent 794 
adverse effects observed in the Phase 2 study, might need to be considered.    795 
(http://investor.cempra.com/releasedetail.cfm?ReleaseID=1014807; February 28, 2017). 796 
Zoliflodacin: The first spiropyrimidinetrione (non-fluoroquinolone topoisomerase II 797 
inhibitor) zoliflodacin targets DNA gyrase (specifically GyrB), but likely also topoisomerase 798 
IV, and has novel mechanisms of action different from all other available 799 
antimicrobials.
197,198,201
 Zoliflodacin initially showed high in vitro activity against 250 800 
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geographically, temporally and genetically diverse wild type, MDR and XDR international 801 
gonococcal reference strains and clinical isolates, with in vitro and clinical resistance to all 802 
currently and previously recommended antimicrobials.
206
 Additionally, consecutive, 803 
contemporary and clinical isolates in Europe (873 isolates from 21 European countries), USA 804 
(100 isolates), and China (187 isolates) have been examined.
211,215,216
 The main zoliflodacin 805 
target in GyrB is highly conserved in clinical isolates.
206
 No cross-resistance with other 806 
available antimicrobials, including the frequently used topoisomerase II inhibitor 807 
ciprofloxacin, has been observed and no zoliflodacin resistant clinical gonococcal isolate has 808 
been identified.
206,211,215,216
 The frequency of induced or selected zoliflodacin resistance 809 
mutations is very low and, interestingly, some of the selected gyrB resistance mutations 810 
appear to increase ciprofloxacin susceptibility.
197,201
  811 
Administering doses ranging between 200-4000 mg to healthy volunteers (18-55 years) in 812 
a Phase 1 study (https://clinicaltrials.gov/ct2/show/NCT02298920),
207
 dose-proportional 813 
increases in plasma concentration up to 800 mg were observed. Doses >800 mg resulted in 814 
slightly smaller dose-proportional increases up to 4000 mg. The median Tmax was 1·5-2·3 815 
hours, and the mean terminal elimination T1/2 was reasonably consistent, ranging between 5·3-816 
6·3 hours. There were no serious adverse events, or drug discontinuations due to adverse 817 
events.
 
Transient dysgeusia (60%), attributed to suspension formulation, followed by mild 818 
transient headache (38%) were the most common adverse events.
198,207
 819 
A Phase 2 RCT evaluating the efficacy, tolerability and safety of zoliflodacin 2 g×1 or 3 820 
g×1 orally for treatment of uncomplicated urogenital gonorrhoea in men and women has been 821 
performed (https://clinicaltrials.gov/ct2/show/NCT02257918).
217
 In total, 48/49 (98%) 822 
patients and 47/47 (100%) patients achieved microbiological cure with zoliflodacin 2 g×1 and 823 
zoliflodacin 3 g×1, respectively. Only 12% of patients reported any adverse events, i.e. mostly 824 
mild gastrointestinal adverse events.
217
 Accordingly, single oral dose of zoliflodacin was 825 
effective and safe for treatment of uncomplicated urogenital gonorrhoea. However, it is 826 
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crucial to examine additional cases of extragenital gonorrhoea, particularly pharyngeal 827 
infection. 828 
Gepotidacin: Gepotidacin is a new non-fluoroquinolone topoisomerase II inhibitor 829 
(triazaacenaphthylene) targeting DNA gyrase (GyrA subunit) and topoisomerase IV (ParC 830 
subunit), but with a different binding mode compared to fluoroquinolones.
200,213
 The 831 
gepotidacin MICs have been shown relatively low, however, the MIC90 was 0·25 mg/L for 832 
108 ciprofloxacin-susceptible isolates and 1 mg/L for 37 ciprofloxacin non-susceptible ones, 833 
indicating some level of cross-resistance to fluoroquinolones.
213 
In vitro studies examining 834 
geographically, temporally and genetically diverse resistant, including MDR and XDR, 835 
gonococcal isolates are ongoing. 836 
The pharmacokinetic profile of gepotidacin was examined in a study including healthy 837 
subjects receiving gepotidacin 800, 1500, 2300, and 3000 mg×1 orally. There are limited 838 
reported data; a reported clearance of 84 L/hour, 9·4-51% variability in clearance, zero-order 839 
absorption, and an absorption lag time.
204 
Administering 2 g×1 orally in six males, 50% was 840 
absorbed. Faecal elimination (53%) predominated, but 20% of total dose was eliminated 841 
unchanged in urine.
209 
842 
A Phase 2 RCT evaluating the optimal oral dose of gepotidacin (1·5 g×1 or 3 g×1 orally) 843 
and efficacy, safety, and tolerability in males and females with uncomplicated urogenital 844 
gonorrhoea has recently been finalised (https://clinicaltrials.gov/ct2/show/NCT02294682), but 845 
the results of this RCT are not publicly available.  846 
 847 
Conclusions 848 
Gonorrhoea is a major public health concern and emergence of gonococcal AMR is 849 
significantly compromising the effectiveness of treatment globally. Improvements in 850 
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treatment, together with clinical and public health actions (table 2), are needed to control 851 
gonorrhoea and AMR in N. gonorrhoeae. Dual antimicrobial therapy (ceftriaxone 250-500 852 
mg×1 plus azithromycin 1-2 mg×1) is recommended for treatment where up-to-date, local, 853 
and high-quality AMR data do not support other therapy.
27,167-172
 This antimicrobial 854 
combination appears to treat almost all gonorrhoea cases and inhibit the spread of AMR 855 
gonococcal strains. Nevertheless, wider availability internationally of other effective 856 
antimicrobials, such as spectinomycin, further studies of the repurposing of old 857 
antimicrobials, particularly gentamicin and ciprofloxacin (following timely molecular 858 
prediction of ciprofloxacin resistance/susceptibility
192
), and in vitro and clinical evaluation 859 
and subsequent licensing of novel accessible and affordable antimicrobials are imperative. 860 
Ideally, these antimicrobials should be used in new dual therapies, in order to preserve them, 861 
and, if oral drugs, in FDCs providing advantages such as increased activity, tolerance, 862 
compliance, lower cost of manufacturing, simpler distribution, and mitigated resistance 863 
development. Several new antimicrobials have proven relatively potent in vitro activity 864 
against gonococcal strains, but clinical data about their effects in gonorrhoea treatment are 865 
lacking.
152,153,156,158,176
 Solithromycin, gepotidacin and particularly zoliflodacin can be 866 
promising for gonorrhoea treatment and deserve further attention.
197-217
 Ultimately, as for 867 
chlamydia, a gonococcal vaccine might be the only sustainable solution for gonorrhoea 868 
control.
150  
 869 
 870 
Part 3. Bacterial vaginosis: reconsidering the evidence for sexual 871 
transmission and implications for research and management 872 
Bacterial vaginosis (BV) is one of the great conundrums in sexual and reproductive health. At 873 
the time of its discovery in the 1950s, “non-specific bacterial vaginitis” was considered likely 874 
to be sexually transmitted. Studies by Gardner and Dukes established the clinical and 875 
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microbiological features of BV in uninfected women following direct inoculation of vaginal 876 
secretions from infected women.
218
 Subsequent work, however, altered this belief. The 877 
apparent absence of an obvious disease counterpart in males, the failure of male partner 878 
treatment trials to consistently reduce BV recurrence in women,
219
 and inability to identify a 879 
sole pathogenic microorganism all contributed. While the approaches used in studies that 880 
treated the male sex partners of women with BV—including study designs, dosing regimens 881 
for male partners and endpoints in female partners—have been criticised,220,221 the general 882 
consensus that BV is not sexually transmitted has persisted.   883 
Advances in molecular techniques, such as 16S rRNA gene sequencing, have confirmed 884 
that BV involves a profound shift in the vaginal microbiota to a dysbiotic state, characterised 885 
by high bacterial species diversity and increased loads of both aerotolerant and strict 886 
anaerobes including Gardnerella vaginalis, Atopobium vaginae and other fastidious BV-887 
associated bacteria such as Megasphaera, Sneathia and Clostridiales species (spp.).
222
 This 888 
change is accompanied by production of volatile amines, a rise in vaginal pH and marked 889 
depletion of key Lactobacillus spp. such as L. crispatus. L. crispatus appears to play an 890 
important role in defence against pathogens through the production of lactic acid, bacteriocins 891 
and other antimicrobial molecules.
223,224
 Recent studies have detected a polymicrobial biofilm 892 
in women with BV that is adherent to vaginal epithelial cells and absent in healthy 893 
controls.
225,226
 But the actual event that triggers this adverse shift in the vaginal microbiota 894 
and the development of biofilm remains elusive. In this section of the Commission, we discuss 895 
the epidemiological and microbiological evidence that supports the role of sexual 896 
transmission in the pathogenesis of incident and recurrent BV. We relate this evidence to the 897 
high recurrence rates following recommended antimicrobial therapy and other treatment 898 
approaches, and discuss the need for novel approaches and combined strategies to address the 899 
burden of disease in women.  900 
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 901 
BV is common and associated with serious reproductive and obstetric sequelae 902 
Globally, women of reproductive age bear a high burden of BV. Prevalence estimates range 903 
from 12% in Australian women,
227
 to 29% in North-American women,
228,229
 to >50% in Sub-904 
Saharan Africa.
230
 When present, symptoms typically include an abnormal vaginal discharge 905 
and an unpleasant fishy malodour. Qualitative studies show that BV is associated with a 906 
significant negative impact on self-esteem, sexual relationships and quality of life.
231
 907 
Although women commonly seek medical evaluation, many report misdiagnosis and 908 
inconsistent clinical management, compounding their distress and confusion.
232,233
 BV is 909 
considered a benign condition, but is associated with serious reproductive and obstetric 910 
sequelae including: a two-fold increased risk of acquiring other STIs; chlamydia, gonorrhoea, 911 
herpes simplex virus type 2 and HIV infection;
18,234-236
 increased risk of transmission of HIV 912 
to male partners,
19
 and increased risk of PID, spontaneous abortion, preterm delivery, low 913 
birthweight, and post-partum endometritis.
237-239
  914 
 915 
Epidemiological evidence for sexual transmission of BV  916 
While the weight and strength of available data support that BV can be acquired through 917 
sexual activity, there has been slow progress in determining the actual transmitted agent or 918 
agents. Epidemiological data have consistently linked sexual exposure to the development of 919 
BV in cross-sectional and longitudinal studies. Detection of BV has been associated with 920 
inconsistent condom use and increased numbers of sexual partners in meta-analyses.
16
 921 
Women with BV have an earlier median age of sexual debut than women without BV.
240
 922 
Although several studies reported BV in “virgins”, the definition was limited to women with 923 
no history of penile-vaginal sex and self-report from potentially vulnerable populations.
241-243
 924 
In contrast, a study of 500 female students collected detailed data on sexual behaviours via 925 
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self-completed questionnaire and employed self-sampling. BV was not detected in women 926 
without a history of sexual activity with others, was uncommon in women who had only 927 
engaged in non-coital sexual activities, and was associated with the practice of penile-vaginal 928 
sex.
244
 Incident BV has been associated with exposure to a new sexual partner,
227,240,245
 while 929 
recurrence after treatment has been associated with sex with an ongoing male partner,
20,246
 930 
suggesting that men may serve as a reservoir for infection and reinfection. Several studies 931 
have found inconsistent condom use increased the risk of recurrence following 932 
treatment.
20,247,248
 Although other behaviours have been associated with BV, including 933 
smoking,
249-252 
douching,
253
 dietary factors,
254
 and stress,
255
 only smoking has been 934 
consistently associated with BV in adjusted analyses. The role of these other practices as 935 
potential co-factors in the development of BV should not be discounted, however.  936 
Epidemiological data consistently show high rates of concordance of BV within female 937 
partnerships.
251,256-259
 BV has been associated with practices that implicate sexual 938 
transmission between women,
251,260
 with incident BV associated with exposure to a new 939 
female sexual partner, a female partner with BV symptoms or a history of BV, and receptive 940 
oral sex in two prospective cohorts.
259,261
 Marrazzo and colleagues showed that monogamous 941 
female couples share Lactobacillus strain types,
262
 and Vodstrcil and colleagues found co-942 
enrolled female couples who did not have BV at enrolment remained with a stable healthy 943 
vaginal microbiota over 24 months in the absence of new partnerships.
259
 Overall, these data 944 
provide evidence to support dynamic exchange of both protective and detrimental vaginal 945 
bacterial species between women in sexual relationships, or transmission of other agents that 946 
directly influence the composition of the vaginal microbiota.  947 
 948 
The elusive male factor  949 
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The apparent lack of symptoms in male partners and the fact that no single transmissible 950 
aetiologic agent has been identified have greatly challenged progress in determining if BV is 951 
sexually transmitted. There is, however, evidence to suggest that BV-associated bacteria or 952 
bacterial communities, perhaps in biofilm form, are transferred between sexual partners. 953 
Molecular sequencing analysis has shown that the sub-preputial space and distal urethra of 954 
men can harbour a broad range of BV-associated bacteria.
263,264
 These BV-associated species 955 
are more prevalent in the male partners of women with BV than without.
17
 In monogamous 956 
couples, specific BV-associated species are highly concordant between women with BV and 957 
their male partners.
265
 Concordance of oligotypes of G. vaginalis has also been reported 958 
among heterosexual couples,
266
 confirming earlier culture-based studies showing concordance 959 
of biotypes of G. vaginalis among heterosexual partners.
267
 Overall, these data indicate sexual 960 
exchange of BV-associated bacterial taxa between heterosexual partners is common,
265
 961 
although it is unclear whether men are actively infected or just transiently colonised. Only one 962 
small study examined male carriage prospectively and the results suggested these organisms 963 
spontaneously cleared over time in men without ongoing sexual exposure.
268
   964 
The composition of the coronal sulcus microbiota is not only influenced by sexual activity 965 
but also by male circumcision.
269
 Male circumcision has been prospectively associated with a 966 
significant reduction in BV-associated genera,
263,264
 and a striking 40-60% reduction in BV 967 
incidence in female partners over 12 months.
270
 Although there are few studies, BV-968 
associated biofilm has been detected in male urine and semen, and more commonly found in 969 
male partners of women with BV than healthy controls.
225,271,272
 Collectively, these data 970 
provide evidence for a sanctuary or reservoir of BV-associated species in men from which 971 
women may either acquire disease, or be reinfected after treatment. Conversely, BV-infected 972 
women may infect or colonise uninfected men, who could be particularly susceptible if 973 
uncircumcised. It is quite plausible that the moist microenvironment of the sub-preputial 974 
space could enhance the susceptibility of uncircumcised men, and could support a higher 975 
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organism load that may facilitate persistence and enhance transmission to women. This 976 
explanation might underpin the ecological association seen in sub-Saharan Africa, where 977 
populations with low rates of male circumcision also exhibit a high prevalence of BV in 978 
women.
230
   979 
The concept of a “symptomatic male disease counterpart” has not received much attention. 980 
In two small studies in the 1980s, however, Keane and colleagues reported that non-981 
gonococcal urethritis (NGU) was more common in male partners of women with BV than in 982 
male partners of women without BV, and that men with NGU were more likely to have 983 
female partners with BV than men without NGU.
273
 In an attempt to explore this further, 984 
Bradshaw and colleagues examined two key BV-associated bacteria, G. vaginalis and A. 985 
vaginae in a case control study of NGU using quantitative PCR, but found neither was 986 
associated with NGU and both were more commonly detected in the urethra of asymptomatic 987 
controls than in men with NGU.
274
 Manhart and colleagues examined the association between 988 
NGU and a broader range of BV-associated bacteria,
275
 and confirmed there was no 989 
association with G. vaginalis or A. vaginae, but found that Leptotrichia/Sneathia were 990 
significantly associated with NGU. BVAB-2, BVAB-3 and Megasphaera were only detected 991 
in men with NGU, but they were uncommon, and there was no statistical evidence of an 992 
association. The only other clinical presentation that has been reported in men is the syndrome 993 
of G. vaginalis-associated balanoposthitis. In a single case report,
276
 three men presented with 994 
a fishy odour, and erythema and irritation of the glans, sulcus and prepuce, all had female 995 
partners with BV, and  G. vaginalis isolated from the glans. So, although a “BV equivalent” 996 
male syndrome does not appear to be common, NGU and perhaps balanoposthitis might be 997 
associated with some BV-associated bacterial species.  998 
 999 
Does treating sexual partners of women with BV improve cure? 1000 
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RCTs conducted in the 1980 and 1990s did not provide consistent evidence for a reduction in 1001 
BV recurrence in women when their male partners were concurrently treated.
277-282
 These data 1002 
formed the evidence base for subsequent BV treatment guidelines that do not recommend 1003 
partner treatment, however, these trials have recently been examined in two systematic 1004 
reviews.
220,221 
Mehta reported that none of the trials had sufficient power to detect reasonable 1005 
effect sizes, randomisation methods were deficient or insufficiently reported, adherence to 1006 
therapy was only reported in males in two trials, and many of the treatment regimens, 1007 
including single dose therapy, would not now be considered effective.
221
 A Cochrane review 1008 
by Amaya-Guio and colleagues concluded that low to very low quality evidence suggests that 1009 
antibiotic treatment does not lead to a lower recurrence rate.
220,221 
Overall the trials are 1010 
considered inconclusive by current standards. The inconsistency between trial findings and 1011 
epidemiological and microbiological data may be explained by a number of factors. The 1012 
findings were clearly influenced by issues in trial design,
221
 but these trials were also 1013 
conducted prior to advances in molecular methods that have provided evidence of detection of 1014 
BV-associated bacteria in the sub-preputial space of males. It is possible that optimal therapy 1015 
to promote clearance of BV-associated bacteria from penile and urethral sites requires a 1016 
combination of both topical and oral antibiotics. Alternatively, it is possible that non-bacterial 1017 
agents such as viruses or bacteriophages, which have been implicated in the pathogenesis of 1018 
BV, are being sexually transmitted, and if this is the case these agents will not be influenced 1019 
by male partner treatment with antimicrobials.    1020 
 1021 
Do bacteriophages play a role in bacterial vaginosis? 1022 
Phage mediated lysis of lactobacilli has been postulated as a cause of BV, but there have been 1023 
very few publications in this area. Kilic and Pavlova reported that lysogeny of Lactobacillus 1024 
species (infection with bacteriophages) in women was common, but that the rate of 1025 
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lactobacillus phage detection was higher in women with BV than without.
283,284  
In in vitro 1026 
studies they demonstrated that phages could infect lactobacilli both from the host and 1027 
different women.
284 
Following this work, Blackwell hypothesised that a sexually transmitted 1028 
lactobacillus phage might destroy healthy lactobacilli allowing secondary overgrowth of 1029 
anaerobes, which could explain why BV behaves epidemiologically like an STI but BV 1030 
recurrence rates were unaffected by male partner treatment.
285
 The phage theory can be 1031 
biologically linked to the association between BV and smoking,
249-252
 as tobacco products 1032 
accumulate in cervical secretions, and the cigarette product benzol(a)pyrone diol epoxide 1033 
promotes phage induction.
249,285
 Blackwell again hypothesized that smoking in women or 1034 
their partners might be associated with BV through tobacco product induction of endogenous 1035 
bacteriophages or sexually acquired phages.
285
 Further studies to clarify if bacteriophages 1036 
play a role in the pathogenesis of BV in women and their male partners are clearly needed. 1037 
  1038 
Limitations of current management and the need for new approaches 1039 
Antimicrobial therapy 1040 
Figure 6 provides a schematic representation of the broad range of approaches that have been 1041 
attempted for the management and prevention of BV. As the inciting event that results in the 1042 
development of BV is unknown, traditional treatment approaches have aimed to reduce the 1043 
vaginal burden of anaerobes and to ameliorate concomitant symptoms. Overall, antimicrobial 1044 
compounds with broad activity against most anaerobic bacteria—metronidazole and 1045 
clindamycin—administered for 5-7 days, appear to achieve relatively high short term cure 1046 
rates (80-90%),
27,286,287
 with use of intravaginal formulations resulting in fewer systemic side 1047 
effects.
288
 Symptomatic BV persists or recurs in 50%-70% of women within 3-6 months, 1048 
however, and long-term recurrence rates approach 80% in certain populations.
246,289-291
 1049 
Possible reasons for this include: re-inoculation with these organisms from an exogenous 1050 
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source (i.e. sexual partner) or an endogenous source (i.e. rectal reservoir); failure to 1051 
completely suppress the growth of BV-associated bacteria (i.e. located within a biofilm); 1052 
persistence of host risk factors (for example, douching or smoking); failure to recolonise the 1053 
vagina with desirable lactobacilli; and transmission of or activation of Lactobacillus phages 1054 
that destroy vaginal lactobacilli.
283-285,292
 None of these mechanisms has been conclusively 1055 
shown to explain the high rates of BV recurrence, or to identify women at increased risk for 1056 
BV incidence, recurrence, or sequelae. If sexual transmission is involved in the pathogenesis 1057 
of BV, as hypothesised, it is still not clear what is being transmitted - a single founder 1058 
organism (a bacterium or virus), a bacteriophage that lyses protective lactobacillus species or 1059 
a polymicrobial bacterial consortium in the form of biofilm. 1060 
Factors that determine whether a woman with BV will respond to standard antimicrobial 1061 
regimens are also not clear. One prospective study indicated that detection of specific BV-1062 
associated bacteria prior to treatment with intravaginal metronidazole predicted treatment 1063 
failure at 30 days.
291
 Investigators have examined whether AMR plays a role and, while 1064 
clindamycin-resistant bacteria have been detected among women treated with vaginal 1065 
clindamycin, their presence was not associated with reduced cure rates.
293,294
 Metronidazole is 1066 
active against Gram-negative anaerobes and Mobiluncus mulieris, but it is less active against 1067 
G. vaginalis, anaerobic Gram-positive cocci and Mobiluncus curtisii, and inactive against M. 1068 
hominis and A. vaginae.
293,294
 Despite that, many of these in vitro non-susceptible species are 1069 
eradicated following metronidazole therapy, indicating that inhibition or elimination of 1070 
metronidazole-susceptible members of the vaginal bacteria in BV might result in a decline in 1071 
some non-susceptible members as well. In an attempt to effect higher BV cure rates, 1072 
investigators have increased the dose and duration of nitroimidazoles. Metronidazole, when 1073 
used as monthly presumptive therapy, was effective in preventing BV over 12 months of 1074 
use.
295
 Twice weekly vaginal metronidazole gel was also found to be effective in suppressing 1075 
BV during use, with the rationale being that suppression of overgrowth of BV-associated 1076 
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bacteria may offer greater symptom relief, and eventually increase the chance of restoration of 1077 
a normal vaginal microbiota.
296
 While a number of prolonged or intermittent suppressive 1078 
regimens appear effective during use, relapse on discontinuation remains common, and none 1079 
has improved long term cure rates in women. Whether treating women with recurrent BV 1080 
with a longer initial course of metronidazole (10-14 days with vaginal gel or oral tablets) or a 1081 
one week course of oral tinidazole will improve cure rates has not been established. One study 1082 
that compared 14 days with seven days of metronidazole treatment found statistical evidence 1083 
of a benefit when cure was assessed seven days after completion of therapy, but not at 21 1084 
days.
248
  1085 
 1086 
Biofilm disruption 1087 
The presence of a BV-associated biofilm might also contribute to the high rates of failure of 1088 
antimicrobial therapy. Biofilms not only reduce antimicrobial penetration enabling susceptible 1089 
microbes to persist, but contain microbes in varying states of metabolic activity with some in 1090 
more dormant inactive states.
292,297,298
 When visualised with specific fluorescent probes, G. 1091 
vaginalis has been detected in large quantities within adherent biofilms among women with 1092 
BV, and some studies indicate that these biofilms persist in women experiencing treatment 1093 
failure.
299,300
 Biofilm disruption might be necessary to achieve optimal efficacy of 1094 
antimicrobials. Agents that display activity against biofilms include: octenidine, boric acid, 1095 
DNAses, retrocycline, and naturally occurring antimicrobials (subtilosin, ploy-L-lysine, and 1096 
lauramide arginine ethyl ester).
301-306
 Boric acid and octenidine are currently the only agents 1097 
to have been evaluated in human studies. While use of metronidazole after 21 days of boric 1098 
acid reduced BV recurrence on treatment, late post-treatment recurrence was common.
301
 1099 
Similarly, early BV cure rates looked promising with intravaginal octenidine, but BV 1100 
recurrence occurred in a significant proportion of women and bacterial resistance to 1101 
octenidine also emerged.
302
 A recent in vitro study showed that metronidazole and tobramycin 1102 
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were highly effective against biofilm formation but ineffective against established biofilm. 1103 
Amphoteric tenside sodium cocoamphoacetate was, however, highly effective in disrupting 1104 
biofilm, reducing biomass by 51% and augmented the effect of metronidazole, indicating that 1105 
this might have potential as a combination approach for BV.
307
 As G. vaginalis biofilms 1106 
contain extracellular DNA, enzymatic disruption by DNase has been shown to inhibit G. 1107 
vaginalis biofilm formation and to disrupt biofilms in vitro.
303
 DNase appears to be even more 1108 
effective in vitro when combined with metronidazole,
303
 but has not yet been subject to 1109 
human studies for BV. RC101, a retrocycline and potent inhibitor of vaginolysin (a toxin 1110 
produced by G. vaginalis), also inhibits the formation of G. vaginalis biofilms in vitro,
305,306
 1111 
and might be another potential candidate for human studies in BV. Lastly, an emerging area 1112 
of research involves inhibition of quorum sensing, a strategy that some bacteria use to 1113 
coordinate expression of genes involved in virulence, biofilm formation and 1114 
pathogenicity.
298,308
 While quorum sensing inhibitors have not been evaluated in human 1115 
studies, they are active in vitro against biofilms produced by Pseudomonas aeruginosa and 1116 
Staphylococcus spp.
308,309
 Overall, the development of safe and effective topical biofilm-1117 
disrupting agents that can be combined with antimicrobials has been suggested as an 1118 
important area of current research.
298 
1119 
 1120 
Approaches to restore a healthy vaginal microbiota 1121 
Because of the apparent ecological shift in the vaginal microflora in BV, therapies that either 1122 
act as vaginal disinfectants or aim to restore the vaginal ecosystem have been evaluated. 1123 
Although repletion of desirable Lactobacillus species would seem to be key, this strategy has 1124 
presented challenges, and probiotic trials to date have not demonstrated consistent benefit.
310
 1125 
One of the barriers to progress has been lack of suitable vaginal species for probiotic 1126 
formulations, but a L. crispatus vaginal capsule, first known as CTV 05 and now termed 1127 
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LACTIN-V, has recently been shown to achieve vaginal colonisation, to be safe
311-313 
and to 1128 
prevent recurrent urinary tract infections in a Phase 2B RCT;
314
 it is now under study for 1129 
treatment of BV. The efficacy of vaginal acidifiers such as lactic acid, in the form of gels, 1130 
suppositories and acid-soaked tampons, has varied widely. Vaginal acidifiers will suppress, 1131 
but not kill, vaginal anaerobes, so may suppress without affecting a cure. A systematic review 1132 
of these agents found they were either ineffective or not adequately tested due to limitations in 1133 
study size, design or analysis, and that more data are needed.
315
  1134 
 1135 
Conclusion 1136 
The adverse impact of BV is felt by the women who experience it, their partners and infants, 1137 
and their health care providers who struggle to effectively treat it. As we have discussed, the 1138 
available epidemiological and microbiological data provide strong evidence of carriage of 1139 
BV-associated bacteria in male genitalia and exchange of either these species within sexual 1140 
partnerships or another agent capable of inciting BV. There is also compelling evidence for 1141 
the impact of male circumcision and condom use on reducing the risk of BV acquisition and 1142 
recurrence. Overall, these data strongly suggest that sexual transmission is an integral 1143 
component of the pathogenesis of incident and recurrent BV. Earlier partner treatment trials 1144 
had substantial methodologic limitations, and do not provide an adequate body of proof to 1145 
discount the possibility that male partner treatment may reduce BV recurrence in women. 1146 
New partner treatment trials, conducted in accordance with current clinical trial standards, and 1147 
employing modern microbiologic tools, are needed to determine the contribution of 1148 
reinfection to recurrence, and to provide an accurate evidence base for treatment guidelines. 1149 
Given the data supporting an anatomic reservoir of BV-associated bacteria in male genitalia, a 1150 
logical approach might emphasise trials that study a potential role of topical antimicrobials in 1151 
addition to oral agents; eradication of cutaneous carriage of these bacteria from the penile skin 1152 
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may reduce the risk of reinfection and optimise BV cure. Female partner treatment trials could 1153 
also facilitate understanding of pathogenesis, and identify new approaches to management. 1154 
While the relative contribution of persistence of BV-associated bacteria versus reinfection to 1155 
BV recurrence is not clear, both mechanisms are likely to play a role. It is also possible that 1156 
other factors including failure to recolonise the vagina with desirable lactobacilli, persistence 1157 
of host risk factors or lactobacillus phages contribute. Ultimately, optimal treatment strategies 1158 
are likely to require combination approaches such as use of antimicrobials, biofilm-disrupting 1159 
agents and partner treatment. Efforts to optimise the therapeutic and preventive approach to 1160 
this complex syndrome will, however, require allocation of the necessary resources and 1161 
commitment be made to a disease that remains largely hidden from public view. Yet BV is 1162 
not rare or benign, it is a condition of high global burden in women of reproductive age and is 1163 
associated with serious and costly sequelae, including preterm delivery and increased risk of 1164 
HIV acquisition and transmission. Recognition for this neglected condition—in the form of a 1165 
coherent, progressive research agenda and concomitant resource allocation—is well past due.  1166 
 1167 
Part 4. STI case management and control in low and middle income 1168 
countries: the role of point of care tests 1169 
In 2012, over 90% of new estimated cases of gonorrhoea, chlamydia, trichomoniasis and 1170 
syphilis were from low and middle income countries (Figure 1).
2
 These curable STIs can lead 1171 
to severe complications and long-term sequelae, burdening already over-stretched health care 1172 
systems. Primary prevention of STIs in low and middle income countries has shown some 1173 
success with vaccines against human papillomavirus (HPV) and hepatitis B and with male 1174 
circumcision, but less so with interventions to promote sustained behaviour change and 1175 
condom promotion.
316
 STI case management and secondary prevention by screening and/or 1176 
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treatment to prevent complications have been hampered largely by the lack of affordable and 1177 
accessible diagnostic tests. Case management of STIs in low and middle income countries has 1178 
relied on syndromic management for patients presenting with symptoms;
133,317
 syndromic 1179 
management, however, has poor specificity, results in overtreatment with antibiotics and does 1180 
not disrupt transmission among those with asymptomatic infection.  1181 
Most low and middle income countries have policies for universal syphilis screening 1182 
during pregnancy for secondary prevention of congenital syphilis. WHO has prioritised the 1183 
elimination of congenital syphilis and Cuba became the first country to achieve the targets for 1184 
elimination of mother-to-child transmission of both syphilis and HIV in June 2015.
33
 1185 
Nevertheless, implementation of antenatal syphilis screening policies is weak in many 1186 
countries. The highest estimates of syphilis prevalence were found in the WHO African 1187 
Region (estimated prevalence amongst antenatal attendees is from 4·6 to 6·5%); the median 1188 
reported proportion of antenatal attendees tested for syphilis was 58% in the African Region, 1189 
versus 83-99% in other regions.
2,318
 The proportion of pregnant women not tested for syphilis 1190 
in antenatal care fell from 2008 to 2012 in all regions except Africa.
319
 The Joint United 1191 
Nations Programme on HIV/AIDS (UNAIDS) published data on the Global Plan towards the 1192 
elimination of new HIV infections and reported that mother-to-child transmission rates of 1193 
HIV were reduced by 71-86% in African countries between 2009 and 2015.
320
 The lack of 1194 
similar progress in syphilis screening in Africa illuminates the tragic reality that many babies 1195 
will have avoided HIV, but died from syphilis.
321,322
 There are few other specific policies for 1196 
control of STIs in low and middle income countries. While most syndromic management 1197 
guidelines include partner notification and treatment, this is often weakly implemented.
323 
1198 
Periodic presumptive treatment in targeted populations, such as commercial sex workers, has 1199 
shown promise but overtreatment with antibiotics is still a concern.
324 
 1200 
Rapid and simple POC tests might provide solutions for both STI case management and 1201 
control. The key features of POC tests are turnaround times that are fast enough to allow 1202 
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completion of testing, communication of results that guide clinical decisions and follow-up to 1203 
take place at the same clinical encounter.
147
 There are affordable highly sensitive and specific 1204 
POC tests for syphilis. While there are several hopeful tests in the pipeline for chlamydia and 1205 
gonorrhoea, the available POC tests have low accuracy or require expensive equipment.
325 
1206 
Yet, even with well performing, affordable POC tests, challenges will remain for 1207 
implementing POC testing into national health systems. This section of the Commission 1208 
reviews current challenges facing case management and STI control related to secondary 1209 
prevention of curable STIs in low and middle income countries, and provides an update of the 1210 
state of the art of POC tests.  1211 
 1212 
Case management of symptomatic STIs in low and middle income countries 1213 
Case management is the treatment of infections to alleviate signs and symptoms, and to 1214 
prevent sequelae, and includes history-taking and clinical examination, diagnostic tests, 1215 
treatment, partner notification, health promotion advice, follow-up and surveillance.
31
 Case 1216 
management is an integral part of an STI control strategy; early treatment can disrupt onward 1217 
transmission if treatment and partner notification are successful. The treatment of clinical 1218 
syndromes, commonly called syndromic management, was developed in the late 1970s and 1219 
early 1980s to address the practical difficulties of managing STIs where diagnostic tests are 1220 
not available.
326
 In 1985, the first WHO guidelines for STI management included four simple 1221 
algorithms for the management of syndromes that are associated with common STIs: genital 1222 
ulcers, urethral discharge, vaginal discharge and PID. Patients are treated for all the probable 1223 
causes of these syndromes. These guidelines gained recognition in the growing HIV epidemic 1224 
in the early 1990s, when the link between STI and HIV became clear, and have become the 1225 
backbone of case management for STIs in many low and middle income countries. The 1226 
current WHO syndromic management guidelines have algorithms for six syndromes: urethral 1227 
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discharge, genital ulcers, scrotal swelling, vaginal discharge, low abdominal pain, and 1228 
neonatal conjunctivitis.
133
 1229 
The advantages of syndromic management include low cost, modest training requirements 1230 
and provision of immediate treatment. The main disadvantage is that syndromic management 1231 
unnecessarily treats for infections that are not present, and misses asymptomatic infections, 1232 
which are the majority of STIs globally.
327
 This is especially true for vaginal discharge 1233 
syndrome which is more commonly caused by BV, candidiasis or trichomoniasis, than by 1234 
chlamydia and gonorrhoea.
43
 Several studies have shown poor sensitivity and specificity of 1235 
syndromic management for chlamydia and gonorrhoea in women.
328-331
 Efforts to increase 1236 
accuracy for the vaginal discharge syndrome with a risk assessment were evaluated, but 1237 
sensitivity and specificity remained poor.
332
 This is because most women with vaginal 1238 
discharge do not have these infections, and most women (up to 70%) with chlamydia and 1239 
gonorrhoea have no symptoms.
17 
Unfortunately, asymptomatic infection is still likely to cause 1240 
harmful sequelae. A study among female sex workers in South Africa has shown that 1241 
cervicovaginal inflammatory markers were elevated in women with an STI whether or not it 1242 
was symptomatic.
331
 Previous studies have suggested that elevated inflammatory markers may 1243 
facilitate HIV transmission,
333
 and thus, women with asymptomatic STIs might be as 1244 
susceptible to HIV infection as those with symptoms. Additionally, it is estimated that the use 1245 
of syndromic management results in the unnecessary treatment of 60-98% of women 1246 
presenting with vaginal discharge for chlamydia and gonorrhoea.
334
 Any use of antibiotics 1247 
encourages resistance, so it is important that the unnecessary use of antibiotics is limited. As 1248 
noted by Unemo in Part 2, increased resistance to most antibiotics used to treat gonococcal 1249 
infections has been reported worldwide, raising concerns about the eventual development of 1250 
untreatable gonococcal infections with serious sexual and reproductive health consequences.  1251 
 1252 
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Partner notification 1253 
In Part 1, Low and Hocking discuss partner notification strategies for the management of 1254 
diagnosed chlamydia. In the context of syndromic management in low and middle income 1255 
countries, partner treatment often results in over-prescription of antibiotics, especially of 1256 
partners of women with vaginal discharge, most of whom do not have an STI.
335
 A systematic 1257 
review of partner notification in developing countries found that partner notification for STIs 1258 
was feasible in low and middle income countries and that most patients diagnosed with STIs 1259 
were willing to self-notify their regular partners.
336
 There are, however, major barriers to 1260 
successful partner notification, including fear of abuse and rejection resulting from partner 1261 
referral, especially for women. Economic vulnerability of women must be considered in the 1262 
design of partner notification strategies in low and middle income countries in which female 1263 
partners may be blamed for the infection.
335
 There is a need for the development and 1264 
evaluation of partner notification strategies in low and middle income countries using 1265 
biological outcomes, such as reinfection.
138  
1266 
 1267 
Targeted presumptive treatment 1268 
Presumptive treatment is the treatment for a presumed infection in populations with a high 1269 
burden of STIs without confirmation of infection by an examination or laboratory test. 1270 
Presumptive treatment for STIs may be given at repeated intervals, in which case it is known 1271 
as periodic presumptive treatment. Periodic presumptive treatment is complementary to 1272 
syndromic management and targets asymptomatic infection in high burden, key populations – 1273 
many of whom are stigmatised and hard to reach, such as female sex workers. Most periodic 1274 
presumptive treatment targets chlamydia, gonorrhoea and syphilis, and it has been most 1275 
extensively evaluated in sex worker populations. In 2005, a WHO consultation reviewed 1276 
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experience from nine countries and recommended that periodic presumptive treatment be 1277 
considered as a part of the package of services to rapidly reduce STI prevalence in sex worker 1278 
settings, particularly where STI control is poor.
337
  In 2012, a systematic review reported the 1279 
results from 15 studies and showed consistent reductions of about 50% prevalence in 1280 
populations with high chlamydia and gonorrhoea prevalence. There was limited evidence for 1281 
chancroid - one study showed rapid decline of chancroid – and mixed evidence for syphilis.338 1282 
Modelling studies have shown that, if sufficient coverage is achieved (>30% of the target 1283 
population), periodic presumptive treatment interventions can effectively reduce the STI 1284 
prevalence among the target population, and that interventions with sufficient coverage 1285 
(≥40%) and follow-up (≥2 years) could significantly decrease HIV incidence (>20%).339  1286 
Presumptive treatment can be an effective approach to the treatment of asymptomatic 1287 
infection among women (at least those at high risk) and may interrupt transmission between 1288 
sex workers and their clients, but needs evaluation in other populations. Importantly, 1289 
presumptive treatment must be sustained; once stopped, infections recur. In addition, a 1290 
disadvantage is unnecessary treatment of people who are not infected with an STI and the 1291 
contribution to the development of AMR, as discussed above.  1292 
 1293 
Screening programmes 1294 
Antenatal syphilis screening and treatment is effective and cost-effective for the prevention of 1295 
adverse pregnancy outcomes.
340
 Fifty-two low and middle income countries reported testing 1296 
coverage for syphilis during antenatal care for 2012, however, only about a third reported 1297 
coverage of at least 95%, whereas another third reported coverage of less than 50%.
317,341
 Of 1298 
14 countries that report current policies for antenatal screening of C. trachomatis and N. 1299 
gonorrhoeae infections, only two (Romania and Bulgaria) are in the category of low and 1300 
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middle income; most low and middle income countries use WHO recommended syndromic 1301 
management for the treatment of symptoms during antenatal care.
342 
 1302 
Screening of high-risk populations, including sex workers has shown some success in 1303 
research studies and demonstration projects,
343,344
 but has not been widely replicated in low 1304 
and middle income countries due to the cost of diagnostics and laboratory capacity.
343
 1305 
Evidence about chlamydia screening is discussed in detail in Part 1.  1306 
 1307 
The use of POC testing for case management and STI control 1308 
POC tests provide prompt diagnosis for case management, provide a definite diagnosis of an 1309 
STI which can further justify and facilitate partner notification, and can be used for screening 1310 
antenatal care attendees and populations at high risk for STIs. There are several low cost 1311 
techniques for STI diagnosis that can be done at the POC, including wet mount and Gram 1312 
stain microscopy, but they require laboratory equipment and lack sensitivity, particularly for 1313 
diagnosing infections in women. Rapid plasma reagin (RPR), a non-treponemal test for 1314 
syphilis, can also be done at the POC, but it requires separation of serum, refrigeration and 1315 
equipment, and has low accuracy in settings with insufficient training or facilities.
345-347
 In 1316 
addition, RPR tests are often batched or sent to a central laboratory, resulting in patients not 1317 
returning or staying for treatment.
345,348,349  
1318 
To guide the development of simple and rapid POC tests, WHO developed the ASSURED 1319 
benchmarking in 2006. ASSURED POC tests are Affordable by those who are at risk for the 1320 
infection; Sensitive, very few false negatives; Specific, very few false positives; User-1321 
friendly, very simple to perform (minimal steps required with minimal training); Rapid and 1322 
Robust, to enable treatment at visit of diagnosis (rapid) and does not require refrigeration 1323 
storage (robust); Equipment free, easily collected non-invasive specimens (e.g. saliva and 1324 
urine) and not requiring complex equipment; and Delivered to end users.
350
 Three recent 1325 
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systematic reviews summarise the available information on POC tests for STIs: Tucker and 1326 
colleagues;
351
 Gaydos and Hardick;
352
 and Herbst de Cortina and colleagues.
353
 Reviews 1327 
evaluated available POC tests and those in the pipeline. The WHO landscape analysis of POC 1328 
tests by Murtagh provides a listing of currently available POC tests and those in the 1329 
pipeline;
325
 this analysis will be updated annually by WHO. Available POC tests have been 1330 
summarised in table 3.  1331 
 1332 
POC tests for chlamydia and gonorrhoea 1333 
Most POC tests currently available for the detection of C. trachomatis or N. gonorrhoeae are 1334 
based on antigen detection in lateral flow devices and do not meet ASSURED criteria because 1335 
of low sensitivity and/or specificity. While the aQcare Chlamydia TRF and BioStar Optical 1336 
Immunoassay for gonorrhoea have been shown to be highly sensitive and specific, both have 1337 
only been evaluated in one study each (for BioStar Optical Immunoassay only a pilot study 1338 
including five confirmed N. gonorrhoeae positive specimens).
354,355
 There is general 1339 
agreement that most current POC tests for the detection of C. trachomatis or N. gonorrhoeae 1340 
do not perform well, and there is a need for improved assays. Nevertheless, modelling studies 1341 
have suggested that even insensitive POC tests may increase the proportion of infections 1342 
treated in scenarios where it would be difficult to ensure a high patient return rate, and in 1343 
populations where there is potential for further STI transmission during the delay in treatment 1344 
from using laboratory STI tests.
356-358
 1345 
GeneXpert (Cepheid, Inc), a NAAT-based test with high sensitivity and specificity for 1346 
detection of C. trachomatis and N. gonorrhoeae has been termed a near-POC test as it 1347 
requires equipment, is expensive and has a relatively long turnaround time (approximately 90 1348 
minutes). There are many new technologies in the pipeline (Figure 7) which are likely to be 1349 
highly accurate and require minimal training and processing time including the io® Platform 1350 
(Atlas Genetics), GeneXpert® Omni (Cepheid), RT Cross-priming Amplification CT Test 1351 
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(Ustar Biotechnologies), Truelab
TM
 Real Time micro PCR System (Molbio Diagnostics Pvt. 1352 
Ltd), Alere
TM
-i Platform (Alere, Inc), CT/NG MAMEF-based detection, and MobiLab (Johns 1353 
Hopkins University BioMEMS Lab).
325,351,353
 The latter test employs smartphones for reading 1354 
results. 1355 
 1356 
POC tests for trichomoniasis 1357 
The OSOM® Trichomonas Test (Sekisui Diagnostics) for detection of T. vaginalis infection 1358 
has been shown to perform well against wet mount and culture (83·3-90·0% sensitivity and 1359 
98·8-100% specificity).
325,353
 The OSOM test for detection of T. vaginalis meets the 1360 
ASSURED benchmark by having few steps and taking only 10 minutes to perform. 1361 
GeneXpert platform also has an assay to detect T. vaginalis and this test has been evaluated in 1362 
two studies and found to be sensitive and specific (95·0-95·6% and 95·7-100% 1363 
respectively);
359,360
 however, the GeneXpert platform does not meet ASSURED 1364 
benchmarking as stated above. In the pipeline, Atlas io
TM
 has an assay in development as well 1365 
as AmpliVue® (Quidel Corporation).
325
  1366 
 1367 
POC tests for syphilis 1368 
Four treponemal POC tests for syphilis have been evaluated and met the ASSURED criteria, 1369 
and these are recommended in resource-limited settings: Determine
TM
 Syphilis TP (Alere, 1370 
Inc), SD Syphilis 3.0 (Alere SD Bioline), Syphicheck® WB (The Tulip Group/Qualpro), and 1371 
Visitect® Syphilis (Omega Diagnostics).
350,361
 These tests are accurate, cost less than $1 if 1372 
purchased through the WHO bulk procurement programme for low and middle income 1373 
countries, can provide results in 15 to 20 minutes, and are easy to use with minimal training. 1374 
In addition to these tests that have been extensively evaluated, other POC tests for syphilis are 1375 
on the market including Crystal TP Syphilis Test (Span Diagnostics), OnSite
TM
 Syphilis Ab 1376 
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Combo rapid Test (CTK Biotech Inc.), Syphilis Health Check
TM
 (Diagnostics Direct), and 1377 
Uni-Gold
TM 
Syphilis Treponemal (trinity Biotech).
325
  1378 
Treponemal POC tests have been implemented and evaluated in rural antenatal care clinics 1379 
in Tanzania, Uganda and China; both rural and urban clinics in Peru and Zambia; and in 1380 
remote indigenous communities in Brazil.
362
 The introduction of POC tests increased the 1381 
proportion of antenatal care attendees screened for syphilis to 90%, and the proportion of 1382 
pregnant women with syphilis who were treated the same day exceeded 90% in all countries. 1383 
Modelling from this study has shown that POC tests are more cost-effective in screening and 1384 
treating syphilis than laboratory-based testing methods such as the RPR.
363
  1385 
Treponemal POC tests have also been used in hard-to-reach populations. In Brazil, health 1386 
care workers in remote communities succeeded in screening 55% of the sexually active 1387 
population (defined as ≥10 years of age) for syphilis, exceeding the 30%–40% target 1388 
originally set.
362
 Modelling studies have estimated the impact of using rapid POC tests to 1389 
screen female sex workers for syphilis and shown that rapid POC test screening could 1390 
dramatically reduce syphilis prevalence amongst this hard-to-reach group, but strategies to 1391 
reduce re-infection from regular non-commercial partners are needed to maximise impact.
364
  1392 
Once a person has been infected with T. pallidum, all future treponemal tests will be 1393 
positive; therefore, there is concern that treponemal POC tests cannot distinguish between 1394 
current and past infection, resulting in over treatment for syphilis. This is particularly 1395 
important in settings in which access to confirmatory testing using non-treponemal tests is 1396 
limited. Therefore, combination POC platform tests have been developed which include both 1397 
treponemal and non-treponemal antigens. The Dual Path Platform test is the first of these, and 1398 
has good sensitivity and specificity for both treponemal (90·1-98·2% and 91·8-98·0%, 1399 
respectively) and non-treponemal (80·6-98·2% and 89·4%, respectively) tests.
365
   1400 
 1401 
POC tests for syphilis and HIV 1402 
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There is also a need for dual syphilis and HIV tests. These could be used in populations at 1403 
high risk for both HIV and syphilis, and accelerate programmes for the elimination of mother 1404 
to child transmission of both HIV and syphilis, especially in countries in Africa that have 1405 
made excellent progress towards the elimination of mother to child transmission of HIV but 1406 
not syphilis. In 2017, WHO published an information note to provide advice for countries 1407 
using or planning to introduce dual HIV/syphilis POC tests in antenatal services and other 1408 
testing sites.
366 
There are currently five combination HIV/syphilis POC tests on the market 1409 
(Figure 8), of which three have published data on sensitivity and specificity: Standard 1410 
Diagnostics (SD) Bioline HIV/Syphilis Duo Rapid Test; Chembio DPP® HIV-Syphilis 1411 
Assay; and Medmira Multiplo Rapid TP/HIV Antibody Test.
325
 In addition to these, there is 1412 
an innovative dual POC test in the pipeline, mChip Assay (Junco Labs and Columbia 1413 
University in collaboration with OPKO Health, Inc),  which uses a microfluidic mChip and a 1414 
smart phone for reading results.
325
  1415 
 1416 
POC tests for AMR gonorrhoea 1417 
There are, as yet, no commercially available diagnostic assays that detect gonococcal 1418 
AMR.
191
 There is an urgent need for the development of these diagnostics with a focus 1419 
towards POC tests. Detection of both N. gonorrhoeae and its main resistance determinants at 1420 
the POC would improve management and help to slow the spread of AMR, particularly in low 1421 
and middle income countries.
191
 1422 
 1423 
Challenges for the implementation of POC tests 1424 
POC tests have the potential to transform case management and STI control in low and 1425 
middle income countries. To be effective at the population level, however, they must be 1426 
adopted by national health systems and this requires careful consideration. Decentralising 1427 
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testing from the laboratory can put tremendous stresses on fragile health care systems in terms 1428 
of supply chain management, training, quality assurance and monitoring impact. 1429 
A study in Peru has shown that the use of POC tests offers an opportunity to improve 1430 
screening coverage for syphilis and other aspects of health systems.
362,367
 Widespread 1431 
adoption and use depends on engaging the authorities; dissipating tensions between providers 1432 
and identifying champions; training according to the needs identified; providing monitoring, 1433 
supervision, support and recognition; sharing results and discussing actions together; 1434 
consulting and obtaining feedback from users; and integrating with other services such as with 1435 
rapid HIV testing.
362,367
 As countries begin to implement POC testing, adequate training and 1436 
quality assurance programmes must be developed in parallel. Smit and colleagues evaluated 1437 
the use of dry blood spots to evaluate quality of POC syphilis and HIV tests in Tanzania, and 1438 
found that quality varied between clinics, which helped to identify which clinics needed 1439 
remedial training.
357
  1440 
Ultimately, POC tests pave the way for self-sampling and self-testing outside of a clinical 1441 
setting including community-based organisations, pharmacies and at home. Home-based 1442 
testing for HIV has been shown to reach wide sections of communities in a diverse range of 1443 
contexts and settings, and is viewed to be the gateway to accessing early treatment and 1444 
care.
368
 However, important lessons can be learned from the roll out of simple and rapid HIV 1445 
POC tests in which the major challenges have been well recognised including poor quality 1446 
control, unreliable supply chains, non-standardised training, and limited number of healthcare 1447 
workers.
369
 Decentralising testing for curable STIs might increase access to testing and 1448 
awareness of STIs, but linkage to the health care system will be critical for diagnostic 1449 
confirmation, treatment, counselling and follow-up.
351
 POC tests that meet ASSURED 1450 
benchmarks are likely to fill an important gap for STI control in low and middle income 1451 
countries, yet the technological innovation of POC tests needs to be mirrored by innovation in 1452 
health care delivery and careful planning for implementation. 1453 
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 1454 
Conclusion 1455 
Low and middle income countries shoulder the majority of global incident cases of STIs, 1456 
yet national health systems are less resourced to manage STI cases or carry out secondary 1457 
prevention. POC tests that meet the WHO ASSURED benchmark could bridge the gap for 1458 
STI case management and control in these settings. Currently there are POC tests for 1459 
syphilis and trichomoniasis which meet the ASSURED benchmark. In contrast, there are no 1460 
ASSURED POC tests for chlamydia or gonorrhoea, and there is an urgent need for the 1461 
development and evaluation of POC tests for these infections, as well as for AMR N. 1462 
gonorrhoeae. Importantly, while development of ASSURED POC tests is a crucial target, 1463 
the successful implementation of POC tests into health care systems for the prevention and 1464 
control STIs is the goal. Indeed, the goal for the implementation of POC tests into antenatal 1465 
screening for syphilis is 100% screening and treatment of syphilis worldwide. Future 1466 
ASSURED POC tests for curable STIs will need to be integrated into syndromic 1467 
management guidelines as well as control strategies such as partner notification and 1468 
targeted presumptive treatment. It will be essential that implementation research guides 1469 
integration of POC tests into current strategies for STI case management and control in low 1470 
and middle income countries. 1471 
 1472 
Part 5. STIs in MSM in the era of biomedical interventions for HIV 1473 
prevention  1474 
A historical perspective provides insights into the epidemiology of STIs in MSM in the 21
st
 1475 
century as we enter a new era of antiretroviral-based biomedical interventions for HIV 1476 
prevention in high income countries. The first relevant trend was the rise in notification rates 1477 
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of gonorrhoea and syphilis in men from the 1960s onwards in countries such as England and 1478 
Wales (Figure 9A) and the USA (Figure 9B). The increase in infections amongst MSM is 1479 
reflected in the rising ratio of male to female notifications in surveillance systems that do not 1480 
record the route of acquisition of STIs. Sexual acts between men were illegal in these 1481 
countries in the 1960s and levels of stigma towards both homosexuality and STIs were still 1482 
extremely high.
370 
The availability of penicillin was already stated to have encouraged 1483 
morally sanctioned behaviours by removing fear as a deterrent, particularly of syphilis.
8
   1484 
Feldman remarked that “to the astute venereologist AIDS is an almost inevitable 1485 
consequence of the increase in sexually transmitted diseases”.371 Rates of gonorrhoea and 1486 
syphilis, and the male to female ratio of infections, reached a peak in the late 1970s (Figures 9 1487 
and 10). Other STIs were also common; 50-70% of MSM had serological evidence of 1488 
hepatitis B infection
372
 and outbreaks of infections, such as lymphogranuloma venereum 1489 
(LGV) were reported.
373  
Infections such as hepatitis A and enteric pathogens, such as Giardia 1490 
lamblia, Entamoeba histolytica and Shigella spp., were common causes of gastrointestinal 1491 
disease in MSM and resulted in terms (now considered inappropriate) such as ‘gay bowel 1492 
syndrome’.374 Given what is now known about the biological effects of STIs to increase both 1493 
infectiousness of, and susceptibility to, HIV,
5
 these infections are likely to have facilitated the 1494 
early spread of HIV before it became clinically manifest as opportunistic infections and 1495 
cancers.      1496 
Links between the opportunistic conditions comprising AIDS, risky sexual practices and a 1497 
history of multiple STIs in MSM were noted early on,
375
 well before a retrovirus was 1498 
discovered as the cause of AIDS. Rates of gonorrhoea and syphilis actually began to fall in 1499 
the late 1970s but the rate of decline accelerated rapidly after the first deaths from AIDS were 1500 
reported in the early 1980s.
123,376,377
 Campaigns that arose in the gay community advised 1501 
MSM to reduce numbers of partners and to use condoms, resulting in the development of the 1502 
terminology of ‘safer sex’ within the context of harm reduction. Government-sponsored 1503 
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public health campaigns for the general population followed.
123
 Figure 9A shows the large 1504 
decline in syphilis notifications in England from 1983 onwards, but notifications of other STIs 1505 
including LGV and other enteric pathogens also fell.
123,373 
By 1994, rates of syphilis and 1506 
gonorrhoea were at their lowest levels since surveillance began (Figures 9A and 10). 1507 
Trends in STIs and sexual behaviour in MSM since the mid-1990s have occurred in the 1508 
context of continued developments and improvements in antiretroviral therapies (ARTs) for 1509 
both HIV treatment and for prevention. Notification rates of syphilis, gonorrhoea and 1510 
chlamydia in MSM have all risen (Figure 10).
378-381
 A review of syphilis in 31 high income 1511 
countries between 2000 and 2013 showed that the male to female ratio increased in all 1512 
geographical regions from 4·1 in 2000 to 7·9 in 2013.
381 
New outbreaks of LGV,
373
 hepatitis 1513 
C, and shigellosis have also appeared, particularly in HIV-infected MSM.
379 
Combination 1514 
ART (cART) became available in the mid-1990s and drastically improved the prognosis for 1515 
people with HIV infection,
382
 changing the nature and course of HIV from a deadly infection 1516 
to a chronic disease. Further advances in the efficacy of cART with less toxic drugs and less 1517 
complicated dosing schedules, together with improvements in monitoring viral load and 1518 
resistance, prompted recommendations for earlier commencement of therapy for HIV-infected 1519 
people.
383 
The first use of cART to prevent, rather than treat, HIV was post-exposure 1520 
prophylaxis (PEP), for short-term prophylaxis to reduce the risk of HIV acquisition after a 1521 
substantial risk of exposure to infection.
384
 Since the mid-2000s, the potential for cART to be 1522 
used to prevent HIV transmission followed research showing that cART reduces HIV 1523 
infectiousness and when HIV replication is suppressed to undetectable levels in plasma, 1524 
transmission can be virtually eliminated.
385,386 
Treatment as prevention (TasP; also known as 1525 
“test and treat”387) refers to a population-level strategy of starting cART as soon as HIV is 1526 
diagnosed, irrespective of CD4 cell count, to suppress viral load and prevent transmission to 1527 
sexual partners.
388
 A regimen of two antiretrovirals, taken as pre-exposure prophylaxis (PrEP) 1528 
to prevent acquisition of HIV during periods of regular high risk exposures, overcomes the 1529 
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limitations of PEP and is the third and most recent way of using cART for MSM to prevent 1530 
HIV.
389-391
  1531 
All three uses of cART for HIV prevention have been accompanied by concern about their 1532 
possible unintended negative consequences for sexual behaviour and STIs,
392
 in an analogy 1533 
with earlier fears about penicillin and syphilis.
8 
These concerns have been framed within the 1534 
risk compensation hypothesis, which was first applied to sexual behaviour to explain why 1535 
increases in condom use were not reflected in reductions in HIV incidence.
393 
Risk 1536 
compensation occurs when an intervention prevents an adverse outcome, paradoxically 1537 
making risk-taking behaviour more attractive; compensatory increases in risky behaviours 1538 
then result in a failure to reduce the adverse outcome. The links between biomedical HIV 1539 
treatment and prevention strategies and sexual risk are dynamic and complex.
22,392 
1540 
Behavioural surveillance amongst MSM, such as surveys carried out yearly in Sydney, 1541 
Australia for 20 years (Figure 11) and the US National HIV Behavioral Survey (NHBS) 1542 
conducted using venue-based sampling in 21 cities in the USA every three years since 1543 
2005,
394,395 
show a gradual decline in condom use could be a manifestation of risk 1544 
compensation with several contributing factors over time. “Treatment optimism” about the 1545 
benefits of improved cART has been associated with increased risky behaviour; MSM with 1546 
stronger perceptions that cART has reduced the threat from HIV and that cART reduces the 1547 
need for safer sex engage more often in risky behaviours such as non-condom receptive anal 1548 
intercourse.
396,397
 “Safer sex fatigue”398 and the adverse effects of HIV on mental health399 1549 
also contribute to sexual risk taking. Serosorting (choosing sexual partners with the same HIV 1550 
serostatus) results in sexual networks stratified by HIV serostatus with reduced condom use
395
 1551 
and increased risk of STI transmission.
400
 In this section of the Commission we give an 1552 
overview of the HIV prevention strategies of PEP, TasP and PrEP and examine evidence of 1553 
whether their use results in risk compensation and increases in STI prevalence in MSM. In the 1554 
discussion, we speculate on the potential influence of biomedical interventions on future STI 1555 
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epidemiology in MSM once implemented more broadly and discuss alternative options for 1556 
STI prevention other than condom use.  1557 
 1558 
Post-exposure prophylaxis (PEP) 1559 
Guidelines for the use of PEP recommend it after both occupational and non-occupational 1560 
exposures with a ‘substantial risk’ of HIV acquisition and with an HIV-positive index or an 1561 
index with an unknown HIV status belonging to a high risk group.
401,402
 The efficacy of PEP 1562 
has not been studied in RCTs, but there is a wide consensus about its effectiveness, based 1563 
mainly on one case-control study in a hospital setting, which found an 81% reduction of HIV 1564 
transmission in the group that used PEP.
384
 The increased availability of PEP led to concern 1565 
that it may increase in risk taking.
403
 Two studies did find a higher risk of non-condom sexual 1566 
behaviour and a higher incidence of HIV in the group of MSM after receipt of PEP but these 1567 
studies did not find a correlation between PEP use and changes in risk behaviour.
404,405
 The 1568 
authors concluded that many MSM requesting PEP simply already belong to a high-risk 1569 
group.
405
 In high income countries, most PEP requests come from MSM, but uptake remains 1570 
low; 183 requests from one large public health centre in Amsterdam, The Netherlands, over a 1571 
five-year period.
406
 Successful awareness campaigns have increased uptake of PEP.
403
 The 1572 
limitations associated with ascertaining exposure and eligibility, and suboptimal effectiveness, 1573 
mean that PEP use is unlikely to have any impact on sexual risk behaviour or STIs at the 1574 
population level.   1575 
 1576 
Treatment as prevention (TasP) 1577 
The concept of using cART to prevent sexual transmission of HIV began with the finding that 1578 
transmission between serodiscordant heterosexual couples was rare when the HIV-infected 1579 
partner had a very low or undetectable level of HIV-1 RNA.
385,386
 Based on these 1580 
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observational studies, the Swiss AIDS Commission stated in 2008 that a serodiscordant 1581 
couple could have non-condom sex if the HIV-infected partner was taking cART with 1582 
sustained viral suppression and no other STI.
407 The “Swiss statement” in effect promoted 1583 
widespread HIV testing and immediate treatment to reduce HIV transmission and catalysed 1584 
the initiation of RCTs to examine the impact of TasP at the population level.
387 
Mathematical 1585 
modelling studies showed how, assuming zero transmissibility with suppressed viral load, 1586 
universal HIV testing and immediate cART could eliminate HIV within ten years of 1587 
implementation.
408 
In 2012, an individual-level RCT in nine countries (HPTN 052, Botswana; 1588 
Kenya; Malawi; South Africa; Zimbabwe; Brazil; India; Thailand; USA) showed that early 1589 
diagnosis and initiation of cART reduced the risk of sexual transmission within stable, mostly 1590 
heterosexual, HIV-serodiscordant couples  by 96% (95% CI 73 to 99%) compared with later 1591 
treatment.
409
 To extrapolate these benefits to a whole population, a sufficiently high 1592 
proportion of all HIV-infected individuals would need receive and adhere to effective cART 1593 
from very early in the course of infection.
410 
The first of the population level trials, a cluster 1594 
RCT in Kwazulu-Natal, South Africa, did not find a reduction in HIV incidence in 1595 
communities that received the TasP intervention.
411 
Suboptimal uptake of testing, particularly 1596 
in young men, and delays in linkage to care are likely to have limited the public health 1597 
benefits of TasP,
412 
even though an earlier ecological study in the same population had 1598 
suggested that HIV-incidence was lower in people living in communities with higher cART 1599 
coverage.
413
 1600 
Risk compensation, STIs and the TasP strategy 1601 
There is little published about the effects of the TasP strategy on sexual behaviour and on the 1602 
incidence of bacterial STIs in MSM. In most countries; ART recommendations have moved 1603 
gradually towards starting treatment at high CD4 counts. At the individual level, in the HPTN 1604 
052 RCT, the frequency of new STIs (syphilis, gonorrhoea, chlamydia infections, and 1605 
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trichomoniasis) detected among heterosexual participants treated immediately was low and 1606 
similar to that in those who received deferred treatment after a median 1·7 years of follow up; 1607 
98% of participants were heterosexual and >95% in both groups reported using condoms.
409
 1608 
At the population level, the effects in the TasP trial in Kwazulu-Natal on behavioural 1609 
outcomes, including condom use, have not yet been published.
411
  1610 
An examination of data from San Francisco, USA provides some insight at the population 1611 
level because the city has both biological and behavioural surveillance data spanning the 1612 
introduction of TasP.
414
 The San Francisco Department of Public Health implemented a TasP 1613 
strategy; cART for all HIV-infected persons regardless of CD4 cell count at publicly funded 1614 
HIV clinics and an expansion of HIV testing services, in 2010, two years before US national 1615 
recommendations changed.
414
 We aggregated published STI surveillance data from 2005 to 1616 
2014 and compared the positivity rates of HIV, syphilis and gonorrhoea and mean numbers of 1617 
partners among self-identified gay and bisexual men before the introduction of the TasP 1618 
strategy nationally (from 2005 to 2009) with the period afterwards (from 2010 to 2014).
329,415-
1619 
417
  Figure 12 shows that the percentage of HIV tests with a positive result was already falling 1620 
and declined from 4·5% in 2005 to 2·5% in 2010. HIV positivity dropped further, from 2·5% 1621 
in 2010 to 1·1% in 2014. In contrast, the positivity rate of early syphilis infections rose 1622 
consistently from 1·9% in 2005 to 4·4% in 2014.
329,415-417
 The gonorrhoea positivity rate 1623 
dropped during the period 2005-2009, but increased from 9·7% to 11·2% in the period 2010-1624 
2014. Behavioural surveillance data show that the mean number of sex partners in the prior 1625 
three years decreased from 5·0 in 2007 to 4·4 in 2009 and then increased from 4·6 in 2010 to 1626 
6.1 in 2013.
418
 The recommendation about TasP in San Francisco was thus temporally 1627 
associated with increases in gonorrhoea, syphilis and partner numbers. Risk compensation 1628 
might have contributed to these trends, although the increase in syphilis began before TasP 1629 
began. In Switzerland, the proportion of HIV-infected MSM in the Swiss HIV Cohort Study 1630 
reporting non-condom sex with both occasional and stable partners had increased slightly 1631 
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from 2000 onwards. A piecewise linear regression analysis showed a sudden change with a 1632 
marked increase in non-condom sex from 2008 to 2013, after the publication of the Swiss 1633 
statement that promoted TasP.
419 
Data from the US NHBS surveys amongst MSM, showed 1634 
that condom use has decreased from 2005 up to 2014 over a large geographic area and that 1635 
these trends were not explained by serosorting, seropositioning, PrEP use or cART 1636 
treatment.
395
 Figures 10 and 11, show rates in the bacterial STI notifications in England and 1637 
the fall in condom use in Sydney, Australia, suggest that opposing trends in STI rates and in 1638 
condom use have taken place over a 20 year period and cannot be attributed to any one factor, 1639 
such as TasP. Nevertheless, there is a consensus that knowledge about the effects of cART on 1640 
reduced infectiousness of HIV have contributed to risk compensation.
22 
A disadvantage 1641 
inherent to TasP is that its success depends on the behaviour of others.
420 
The uninfected 1642 
person has to trust that their HIV-infected sexual partners are adherent to cART and that the 1643 
cART is sufficiently effective to mitigate transmission risk. In contrast, with PrEP and PEP, 1644 
the at-risk individual takes the preventive treatment.  1645 
 1646 
Pre-exposure prophylaxis (PrEP) 1647 
Three RCTs have studied the effects of PrEP on the acquisition of HIV infection as part of an 1648 
HIV prevention package for MSM that includes risk reduction counselling, condom provision 1649 
and regular HIV and STI testing.
389-391
 Across these trials, the use of tenofovir disoproxil 1650 
fumarate/emtricitabine (TDF/FTC), in combination with comprehensive sexual health care, 1651 
reduced HIV incidence ranging from 44% to 86%. Two of the RCTs studied daily use of 1652 
TDF/FTC
389,390
 and one studied intermittent use (two tablets between 24 and 2 hours before 1653 
sex, followed by two times one tablet at 24 and 48 hours after sex).
391
 The first landmark 1654 
study, the Preexposure Prophylaxis Initiative (iPrEX), looked at the effect of daily TDF/FTC 1655 
among 2499 MSM from six countries (Peru, Ecuador, South Africa, Brazil, Thailand and the 1656 
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USA) and was published in 2010.
389
 The Pre-exposure option for reducing HIV in the UK, 1657 
immediate or Deferred (PROUD) trial enrolled 544 MSM in the UK and randomised them to 1658 
immediate or a one year delayed start of daily oral TDF/FTC.
390
 In the Intervention 1659 
Préventive de l’Éxposition aux Risques avec et pour les Gays (Ipergay) trial, 414 MSM were 1660 
randomised to either TDF/FTC or placebo for intermittent use in France and Canada.
391
 In all 1661 
PrEP trials, adherence was a strong determinant of PrEP effectiveness.
421
 1662 
These trials showed that it is feasible to identify and enrol MSM at high risk of acquiring 1663 
HIV infection, with HIV incidence rates in the placebo arm of 9·0 per 100 person years in 1664 
PROUD and 6·6 per 100 person years in Ipergay. Open label studies, demonstration projects 1665 
and cohort studies provide additional evidence that PrEP roll-out to MSM at high risk for HIV 1666 
infection is feasible, safe and prevents HIV.
421-424
 Eligibility criteria in most PrEP trials and 1667 
demonstration projects include well-known determinants for HIV acquisition in MSM such as 1668 
recent rectal or urethral STIs, a recent use of PEP, reporting anal intercourse with casual 1669 
partners and having an HIV-positive partner with a detectable viral load.
421
 International 1670 
guidelines for PrEP from the US Centers for Disease Control and Prevention and WHO 1671 
reflect these eligibility criteria.
329,425
  1672 
 1673 
Risk compensation, STIs and PrEP 1674 
PrEP is a powerful intervention for HIV prevention among MSM, but it has the potential to 1675 
reduce commitment to primary prevention strategies, result in risk compensation
392
 and 1676 
increase rates of STIs. The role of PrEP in relation to sexual behaviour and STI rates is 1677 
somewhat easier to assess than with TasP because PrEP is an individual intervention rather 1678 
than a population-based one. PrEP is, however, only in the early stages of implementation.  1679 
In the placebo-controlled trials iPrEx and Ipergay, condom use and STI incidence were 1680 
similar in participants allocated to PrEP and to placebo. These findings are expected because 1681 
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participants were blinded and all received the same risk reduction advice. The PROUD RCT 1682 
was designed as a pragmatic open-label study that would allow risk compensation to be 1683 
observed. The total number of different anal sex partners was similar in the two groups, but a 1684 
larger proportion of participants allocated to immediate than deferred PrEP reported non-1685 
condom receptive anal sex with ten or more partners (21% vs. 12%, p=0·03). The proportions 1686 
diagnosed with STIs during the 12 month follow-up period were similar in men receiving 1687 
immediate and deferred PrEP, however; rectal gonorrhoea or chlamydia, 36% vs. 32% (odds 1688 
ratio, OR 1·00, 95% CI 0·72 to 1·38), syphilis, 11% vs. 9% (OR 1·32, 95% CI 0·79 to 2·10). 1689 
Open-label studies should allow a more realistic assessment of the influence of PrEP on 1690 
sexual behaviour. In an open-label observational study that included MSM who had taken part 1691 
in the iPrEx trial and two other studies, the proportions reporting non-condom receptive anal 1692 
intercourse, non-condom insertive anal intercourse, and numbers of sexual partners all 1693 
decreased to a similar extent during follow-up in both groups and syphilis incidence (7·2 1694 
infections per 100 person years in PrEP recipients and 5·4 per 100 person years, hazard ratio 1695 
1·35, 95% CI 0·83 to 2·19) was also similar.
422 
The authors concluded that there was no 1696 
evidence of risk compensation during open label access to PrEP use, but that cohort 1697 
participation and access to comprehensive prevention services might have encouraged other 1698 
safer sexual behaviours. In the Demo project in San Francisco, Washington DC and Miami, 1699 
USA, early findings (up to 48 weeks) amongst men receiving PrEP have shown a stable 1700 
proportion overall reported having had non-condom receptive anal sex in the previous three 1701 
months (65·5%; 365/557), although the mean number of condom-protected sex acts 1702 
decreased. The proportions with early syphilis, gonorrhoea and chlamydia at quarterly visits 1703 
initially fell and then returned to baseline values.
423
 Qualitative data from participants suggest 1704 
that men integrate PrEP in a dynamic way into existing risk reduction strategies, rather than 1705 
relying on it as a solitary method of HIV prevention.
426
     1706 
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The longer term impact of PrEP for risk compensation and STI rates are not yet known. 1707 
Taken together, trials of PrEP with one to two years of follow up show a large reduction in 1708 
HIV incidence in MSM who adhere to the regimen, high but similar levels of bacterial STIs in 1709 
MSM who received and did not receive PrEP and mixed effects on sexual 1710 
behaviours.
395
Additional studies suggest that increasing use of PrEP as a method of 1711 
biomedical HIV prevention could change patterns of sexual partner seeking and condom 1712 
use.
394,427 
Newcomb and colleagues have coined the term “Biomed-matching” as a new 1713 
strategy amongst MSM who meet up using geosocial networking applications and disclose 1714 
their use of biomedical HIV prevention medication; they then have non-condom anal sex 1715 
when the partner is also taking PrEP or has undetectable viral load on cART.
427 
MSM who 1716 
receive PrEP will need to be followed carefully over time using both quantitative and 1717 
qualitative research methods to determine whether and how risk compensation and changing 1718 
patterns of sexual partnerships and practices are affecting STI rates.  1719 
 
1720 
STI prevention in the era of biomedical HIV prevention  1721 
The use of cART to prevent HIV acquisition and transmission,  TasP and PrEP in particular, 1722 
are changing the HIV prevention landscape for MSM. The continued fall in HIV positivity in 1723 
San Francisco, USA has been attributed to TasP and a rapid increase in the number of MSM 1724 
using PrEP in London, UK might have influenced a 40% reduction in new HIV diagnoses in 1725 
2016 compared with 2015.
428
 Trends in HIV infection and other STIs seem to have been 1726 
decoupled. STI rates in MSM have been rising since the late 1990s (Figure 10).
427,429 
The 1727 
increases in notifications of bacterial STI appear to be accelerating (Figures 9, 10 and 12). In 1728 
England, HIV-infected MSM account for almost all of the increase in STI notifications in 1729 
MSM; for syphilis, the proportion diagnosed in HIV-infected MSM increased from around 1730 
25% in 2009 to around 40% in 2013.
379
 In the absence of denominator data, how much of the 1731 
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increase is the result of more frequent testing is not known. Widening PrEP use, together with 1732 
other behavioural changes, including an increase in the adoption of seroadaptive 1733 
behaviours
394,395
 and use of geosocial networking mobile applications, such as Grindr,
427,429
 1734 
could affect sexual networks and influence rates and patterns of STI. For example, if non-1735 
condom sex partnerships between HIV-uninfected MSM using PrEP and HIV-infected MSM 1736 
on cART become more common, outbreaks of syphilis, LGV, hepatitis, and shigellosis that 1737 
have occurred mostly amongst HIV-infected MSM could spread to networks of HIV-1738 
uninfected MSM. STIs that increase HIV infectiousness through inflammatory mechanisms
5
 1739 
could then reduce the impact of biomedical HIV prevention methods. Additional  surveillance 1740 
and interventions to control STIs amongst MSM in this new era are needed, especially if 1741 
behavioural risk reduction interventions cannot reverse trends in condom use. 1742 
Treatment of curable STIs has long been considered an integral component of combination 1743 
HIV prevention packages.
430
 Regular STI testing to detect and treat asymptomatic infections 1744 
is now widely recommended for STI control in MSM. MSM starting PrEP are advised to be 1745 
tested for bacterial STIs every three months and MSM in general are usually advised to be 1746 
tested every year, although only about 40% of at-risk MSM in Australia were receiving 1747 
annual screening in 2014.
87
 One mathematical modelling study suggested that screening 1748 
MSM for chlamydia could reduce the prevalence of both chlamydia and HIV.
431
 These 1749 
findings should be considered in the light of evidence presented in two other sections of the 1750 
Commission. First, modelling studies also suggest that chlamydia screening in heterosexual 1751 
populations will reduce chlamydia prevalence,
105,106
 but evidence from RCTs
14,95
 and repeated 1752 
population-based cross-sectional studies
43,44
 have not found appreciable reductions in 1753 
chlamydia prevalence in the target populations (Part 1). Second, as AMR in N. gonorrhoeae 1754 
spreads (Part 2), the potential impact of increasing STI testing rates also needs to be 1755 
considered. Mathematical modelling studies of MSM populations show that, at least for some 1756 
antimicrobials, increasing the rate of gonorrhoea treatment might reduce prevalence 1757 
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temporarily, but that the increased selection pressure accelerates the spread of AMR, resulting 1758 
in increased prevalence over time.
432,433
 On the other hand, models of syphilis transmission 1759 
have shown a reduction in incidence with frequent testing and one ecological study using 1760 
national surveillance data in Australia showed that when syphilis testing rose from 1·6 tests a 1761 
year to 2·3 tests a year, there was a reduction in secondary syphilis cases (from 45% to 1762 
26%).
434,435 
There was also a commensurate rise in early late infections (from 23% to 45%) 1763 
suggesting that frequent testing was detecting syphilis infection before it reached the 1764 
secondary stage.
434 
 1765 
Another possible STI intervention that has undergone limited investigation is daily use of 1766 
doxycycline.
436
 A single small double blind randomised trial of 30 individuals followed for 1767 
one year showed lower rates of STI in the doxycycline arm.
437 
Interventions involving 1768 
prophylactic use of antimicrobials have not been pursued further because of concern about 1769 
AMR. One group is investigating the use of antibacterial mouthwash for the prevention of 1770 
pharyngeal gonorrhoea. The hypothesis is that saliva, used as a lubricant for both anal sex and 1771 
oral sex, gives pharyngeal gonorrhoea a central role in the persistence of gonorrhoea at all 1772 
anatomical sites in MSM, even though relatively little is known about the transmission of 1773 
STIs between anatomical sites in MSM.
438 
Mouthwash has been shown in laboratory 1774 
experiments to inhibit N. gonorrhoeae growth and when used in individuals with pharyngeal 1775 
gonorrhoea, it reduces the chance of detecting N. gonorrhoeae five minutes later.
439 
Longer 1776 
term prevention studies are underway using mouthwash. More research is required on STI 1777 
control in MSM that does not rely on condom use including a better understanding of 1778 
infectiousness and transmission between anatomical sites in men.   1779 
 1780 
Conclusions 1781 
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Rates of bacterial STIs in MSM have been rising for about 20 years now and are approaching 1782 
the levels seen in the late 1970s before HIV first appeared. During this time ART strategies 1783 
have become powerful and important methods for HIV prevention. Evidence for a major 1784 
contribution of TasP and PrEP to reductions in future HIV incidence and prevalence is 1785 
accumulating. Risk compensation in response to the success of cART in reducing the 1786 
infectiousness of and susceptibility to HIV, mediated through increases in non-condom sexual 1787 
intercourse or increased numbers of sexual partners, has occurred.
22,390
 The contributions of 1788 
behavioural responses to the biomedical HIV prevention strategies and of other factors 1789 
influencing sexual behavioural change remain unknown.
394,423,427
 Quantifying the effect of 1790 
biomedical HIV prevention interventions on STI rates is methodologically difficult.
377,379 
1791 
Based on surveillance data from places with large populations of MSM,
329,379 
it is likely that 1792 
the incidence and prevalence of STI in MSM will continue to increase. 
 
1793 
STI control interventions that complement the highly effective biomedical interventions for 1794 
HIV prevention are needed as part of combination prevention packages. Indeed, biomedical 1795 
HIV interventions play a positive role in STI control through frequent contacts with sexual 1796 
health services that allow regular continued opportunities for primary prevention and 1797 
comprehensive case management of STIs including prompt diagnosis and treatment, partner 1798 
notification, condom promotion and risk reduction interventions.
440
  1799 
Nevertheless, continued research is needed to investigate and understand the effects of 1800 
TasP and PrEP on sexual behaviours and networks that might increase STI transmission and, 1801 
through STI-HIV interactions, might drive renewed HIV transmission. Enhanced biological 1802 
and behavioural surveillance activities are needed to monitor changes in STIs in HIV-1803 
uninfected and HIV-infected MSM, AMR, and the emergence or re-emergence of new 1804 
sexually transmissible pathogens including enteric infections and Ebola and Zika viruses.
441
  1805 
 1806 
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Call to action 1807 
Action is required to address the substantial challenges facing STI control globally (table 4). 1808 
AMR in N. gonorrhoeae is increasing relentlessly and adverse consequences of chlamydia 1809 
infection remain prevalent. STIs in MSM are rising rapidly, new sexually transmissible 1810 
infections are emerging or re-emerging and there is evidence that BV, one of the most 1811 
common, but often ignored, genital conditions in women, might also be sexually 1812 
transmissible. These issues are magnified in low and middle income countries that bear the 1813 
burden of STIs worldwide. To address these issues we need to reach our policy makers and to 1814 
convince them to invest in clinical and public health strategies to improve the control of STIs, 1815 
based on carefully considered analytical decisions, founded in science. If they do not, we may 1816 
suffer more than we should, and spend more than we need.
442
 In putting this case, we 1817 
recognise that social, cultural and structural conditions are major determinants of sexual 1818 
behaviour, sexual risk and STIs.
443
 Research evidence provides the scientific support for 1819 
prioritising interventions, but successfully influencing health policy will require the 1820 
involvement of stakeholders, including researchers, clinicians, and members of civil society 1821 
as well as policy makers themselves.
444
  1822 
One of the most important messages about STI control is that good policy decisions matter 1823 
much more than poor individual ones.
442,445,446
 This is because effective policy interventions 1824 
can put strong downward pressure on STI incidence,
33
 while individual behaviour has a 1825 
relatively weak effect on the population prevalence of STIs and sustained and substantial 1826 
behaviour change is difficult to achieve.
442,446,447
 We need to make the case to policy makers 1827 
that STIs cost less to keep under control than to treat, and manage their sequelae, when 1828 
endemic levels are high.
442
  1829 
The cornerstone of the health sector response to effective STI control is easily accessible 1830 
quality health care, and is the principle behind the provision of free STI services in many 1831 
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countries.
445
 Accessible health care helps to ensure that STIs are treated early, before 1832 
substantial transmission can occur.
33
 Communities with poor access to health care have high 1833 
rates of symptomatic STIs such as gonorrhoea or trichomoniasis, and those with accessible 1834 
health care have much lower rates, even though the number of sexual partners in both 1835 
communities might be similar.
448
 For example, gonorrhoea in heterosexuals is relatively easy 1836 
to control with accessible primary health care and, as a result, most high income countries 1837 
rates of reported gonorrhoea are well below 100 per 100,000 population. Rates in 1838 
heterosexuals exceed these levels in high income countries in populations whose access to 1839 
health care is limited, such as among uninsured Americans or Indigenous Australians living in 1840 
remote communities.
448,449
 STI services are a key goal of the WHO strategy to help achieve 1841 
universal health coverage, a key target of the 2030 Agenda for Sustainable Development.
33
 1842 
We call on policy makers to ensure their citizens have accessible, affordable and quality STI 1843 
care.
 
1844 
Largely asymptomatic STIs such as chlamydia provide a much greater challenge to 1845 
control. Despite substantial proportions of the population being tested for chlamydia in some 1846 
high income countries it has proven difficult to reduce the prevalence and we remain 1847 
uncertain about the long term impact that widespread testing for chlamydia has on the key 1848 
health outcomes including PID, ectopic pregnancy and infertility. Chlamydia control 1849 
strategies should define acceptable local targets for chlamydia prevalence, so that appropriate 1850 
interventions can be prioritised. Improving case management of those diagnosed with 1851 
chlamydia and PID (e.g. effective antimicrobial treatment, partner notification and retesting to 1852 
detect repeated infection) might achieve more than promoting widespread testing alone. We 1853 
should also establish and adapt surveillance systems so that we know what impact our 1854 
chlamydia control activities are having on PID and its complications. We call on policy 1855 
makers to invest in the research agendas that has been repeatedly called for by international 1856 
experts,
60,150,151,450
 to further our understanding about the natural history of chlamydia and 1857 
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develop non-invasive measures of tubal infection, inflammation and damage and biomarkers 1858 
to predict upper genital tract pathology. Further we must invest in chlamydia vaccine research 1859 
because without an effective vaccine, it is unlikely that we will be able to control it. 1860 
The effective control of gonorrhoea is a global health priority
33
 because of the relentless 1861 
rise in AMR, and the high incidence in low and middle income countries and increasing 1862 
incidence in key populations, including MSM (Figure 10).
379
 In this context we call on policy 1863 
makers to ensure adequate and sensitive surveillance programmes are in place and industry to 1864 
support the development of effective agents should the current ones fail. The control of 1865 
gonorrhoea in MSM presents a similar problem to chlamydia because asymptomatic 1866 
pharyngeal and rectal infection are common and frequently occur in the absence of concurrent 1867 
symptomatic urethral infection, so cases are only detected through testing or partner 1868 
notification.
451
 Some have advocated more frequent screening, but at least with some 1869 
antimicrobials an increased rate of gonorrhoea treatment might accelerate the spread of AMR 1870 
and might outweigh any gains in reducing prevalence.
433
 Another problem with gonorrhoea 1871 
control in MSM is that it is not prevented by consistent condom use for anal sex, because the 1872 
pharynx appears to play a key role in transmission of both infection and AMR.
157,452,453
 1873 
Effective control will require understanding how gonorrhoea is transmitted between MSM so 1874 
evidence-based interventions can be developed just as interventions for HIV control were 1875 
developed by understanding its transmission. Ideally condoms should not be a critical part of 1876 
these interventions given condoms rates are falling and may fall further.
453
 Recent research 1877 
has suggested a potential non-condom based intervention.
439
 Researchers have found that N. 1878 
gonorrhoeae is commonly present in the saliva of men with pharyngeal infection, and that 1879 
saliva is frequently used as a lubricant for anal sex.
454
 Early work has shown that antibacterial 1880 
mouthwash might inhibit N. gonorrhoeae growth and studies of mouthwash for gonorrhoea 1881 
prevention are underway.
439
 We call on policy makers to fund research to better understand 1882 
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how STIs are transmitted between MSM to allow the development of new control 1883 
programmes not based only around condoms.    1884 
BV in women is another commonly asymptomatic infection with a substantial global 1885 
burden that poses similar control issues to chlamydia but has the additional problem that there 1886 
is a lack of a proven transmitted pathogen. Effective control is complicated by its high relapse 1887 
rate which is likely to be due, at least in part, to our failure to recognise the importance of 1888 
sexual transmission in its pathogenesis and the contribution of reinfection to recurrence.
20,246
 1889 
Current treatment strategies are entirely focused on the female partner, while accumulating 1890 
epidemiological and microbiological data provide evidence of male carriage and exchange of 1891 
BV-associated bacteria within sexual partnerships.
265,423
 In order to make significant advances 1892 
in the treatment and prevention of BV and its costly sequelae we need to better understand the 1893 
contribution of persistence of BV-associated bacteria versus reinfection to BV recurrence. 1894 
New treatment strategies are required but we also need to revisit male partner treatment trials 1895 
with more evidence-based approaches.    1896 
Effective STI control in low and middle income settings provide a particular challenge 1897 
because of the high cost of diagnostic tests and limited laboratory capacity that accompany 1898 
weak health service infrastructure. POC tests that fulfil the WHO ASSURED benchmarking 1899 
programme can play an important role in effective STI control, but understanding their 1900 
limitations is critical. Policy makers should fund programmes that optimise and evaluate all 1901 
aspects of STI control in low and middle income counties with the implementation of the 1902 
validated POC tests including, but not limited to, screening of antenatal care attendees and 1903 
high risk populations, improved partner notification strategies, and symptomatic case 1904 
management. Policy makers should fund programmes that optimise and evaluate all aspects of 1905 
STI control including, but not limited to, improved partner notification programmes, 1906 
presumptive treatment, POC tests, syndromic management and combinations of all of these.   1907 
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It is important to acknowledge that STI control strategies that rely only on reducing sexual 1908 
risk practices at a population level will not work well because on their own, they afford a 1909 
relatively modest effect on STI prevalence. Large multicentre studies of behavioural 1910 
interventions for condom use for example have relatively modest effect sizes (~20% effective 1911 
at one year).
446,447
 In contrast, biomedical interventions such as the HPV vaccine programme 1912 
in women have been outstandingly successful and resulted in almost complete elimination of 1913 
the oncogenic HPV in the vaccine in both vaccinated women and unvaccinated heterosexual 1914 
men in Australia.
11,455 
Similarly large effect sizes for reducing HIV acquisition are seen in 1915 
RCTs of PrEP when adherence levels are high.
389-391
 Biomedical methods to prevent HIV 1916 
have, however, contributed to increased rates of STIs amongst MSM as a result of risk 1917 
compensation. No single measure will effectively control all STIs at a population level. 1918 
Effective STI control will require the political will to prioritise and invest in new 1919 
interventions together with the optimisation of both primary and secondary prevention 1920 
strategies including; integrated sex education programmes in schools, strong partner 1921 
notification programmes that utilise the latest information technology systems and legislative 1922 
changes for partner delivered antibiotic treatment where appropriate, legalised frameworks for 1923 
sex work, active targeted health promotion, accurate surveillance programmes and of course 1924 
accessible health care for all.1925 
  1926 
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FIGURE LEGENDS  1927 
Figure 1: WHO estimates of the number of cases (in millions) of four curable STIs 1928 
trichomoniasis (TV), chlamydia (CT), gonorrhoea (NG), and syphilis (TP) globally in 1929 
2012. Source: reference
2
 1930 
Figure 2: Natural history and sequelae of Chlamydia trachomatis infection in women. 1931 
Length of arrows are not proportional to time. Dotted lines are conditions that can 1932 
resolve.  1933 
Figure 3: Interventions for the control of chlamydia in the population. Source: 1934 
reference
31
  1935 
Evidence
31
-based case management includes partner notification, prevention of re-infection 1936 
[advice on sexual behaviour and condom use] and re-testing within a recommended time 1937 
period after treatment)  1938 
Figure 4: Chlamydia prevalence estimates among sexually experienced women ≤26 1939 
years estimated in cross sectional suveys of randomly sampled individuals from the 1940 
general population in WHO regions. 1941 
Source: 1942 
Europe 1943 
Croatia (N=151);
46
 France (N=106);
38
 The Netherlands (N=2626);
41
 Norway (N=930);
42
 1944 
Slovenia (N=265);
40
 Spain (N=157);
49
 United Kingdom (N=992)
44
 1945 
Americas 1946 
USA (N=unavailable);
45
 Argentina (N=148);
49
 Colombia (N=278)
49
 1947 
Africa 1948 
Nigeria (N=120)
49
 1949 
South-East Asia 1950 
China 1 (N=194);
52
 China 2 (N=46);
49
 India;
50
 Thailand 1 (N=69);
49
 Thailand 2 (N=129);
49
 1951 
Vietnam 1 (N=158);
49
 Vietnam 2 (N=123)
49
  1952 
Western Pacific 1953 
Australia (N=135);
39
 Papua New Guinea (PNG; N=73)
51
   1954 
Figure 5: Hospital discharge rates for inflammatory disease in female pelvic organs. 1955 
Source: reference
122
 1956 
See supplementary table 1 for further detail.
122 
 1957 
Figure 6: Interventions attempted for the management and prevention of bacterial 1958 
vaginosis 1959 
Figure 7: Point-of-care (POC) or near-POC tests for STIs that are available or in the 1960 
pipeline. The dotted line means that no market launch date has been set by the 1961 
company. Source: updated from reference
325
 XenoStrip-TV
TM  
rapid diagnostic test for T. 1962 
vaginalis (Xenotope Diagnostics, Inc, San Francisco, USA),
 
OSOM® rapid diagnostic test for 1963 
T. vaginalis (Sekisui Diagnostics, Lexington, USA); GeneXpert® for C. trachomatis, N. 1964 
gonorrhoeae, duplex C. trachomatis and N. gonorrhoeae, T. vaginalis, HPV (Cepheid Inc., 1965 
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Sunnyvale, USA); AmpliVue® for T. vaginalis (Quidel Corporation, San Diego, USA); Atlas 1966 
io
TM
 for
 
C. trachomatis, duplex C. trachomatis and N. gonorrhoeae, T. vaginalis (Atlas 1967 
Genetics, Trowbridge, UK); Truelab
TM 
Real Time micro PCR System for C. trachomatis, N. 1968 
gonorrhoeae (Molbio Diagnostics Pvt. Ltd., Goa, India); Alere
TM
-i for duplex C. trachomatis 1969 
and N. gonorrhoeae (Alere Inc., Waltham USA); GeneXpert® Omni for duplex C. 1970 
trachomatis and N. gonorrhoeae, HPV (Cepheid Inc., Sunnyvale, USA); Cobas® Liat 1971 
Analyser (Roche, Basel, Switzerland); RT CPA C. trachomatis (Ustar Biotechnologies, 1972 
Hangzhou, China); PanNAT® (Micronics, Inc., Portsmith, USA). 1973 
Figure 8: Point-of-care tests for dual syphilis and HIV diagnosis that are available. 1974 
Source: updated from reference
325
 Standard Diagnostics (SD) Bioline HIV/Syphilis Duo 1975 
Rapid Test (Alere, Waltham USA)/(Standard Diagnostics, Republic of Korea); DDP 1976 
®HIV-Syphilis Assay (Chembio Diagnostic Systems, Inc., Medford, USA); Multiplo Rapid 1977 
TP/HIV Antibody test (MedMira, Inc., Halifax, Canada); INSTI Combined HIV/Syphilis 1978 
test (Biolytical Laboratories Inc., Richmond, Canada); mChip Assay (Junco Labs, 1979 
Columbia University, New York, USA in collaboration with OPKO Health, Inc., Miami, 1980 
USA). 1981 
Figure 9A: Notifications of infectious syphilis 1950-2015 by sex and male:female ratio 1982 
in England and Wales. Source: Public Health England.  1983 
Figure 9B: Primary and Secondary Syphilis in the US 1995-2015 by sex and 1984 
male:female ratio in United States. Source: Centres for Disease Control and 1985 
Prevention. 1986 
Figure 10: Notifications of HIV, syphilis (primary, secondary, early latent), gonorrhoea 1987 
and chlamydia, 1996-2015 in men who have sex with men, England. Source: 2001-2015, 1988 
Public Health England (https://www.gov.uk/government/statistics/hiv-annual-data-tables), 1989 
2000 and earlier, National Archive (http://webarchive.nationalarchives.gov.uk/). cART, 1990 
combination antiretroviral therapy; cPEP, combination post-exposure prophylaxis; Swiss 1991 
statement; TasP, treatment as prevention; PROUD results made public. 1992 
Figure 11: Condom use for anal sex among men who have sex with men in Sydney, 1993 
Australia 1997-2016.  Source: Gay Community Periodic Survey   1994 
Figure 12: Percentage of tests positive for HIV, primary and secondary syphilis and 1995 
gonorrhoea, 2005-2014, and mean number of sexual partners in last three months, 2008-1996 
2013, San Francisco, USA. Source: San Francisco Department of Health.  1997 
 1998 
  1999 
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Antimicrobial 
(other 
names) 
Class Mode of action Bacterial target 
(known resistance 
mutations) 
In vitro activity 
against Neisseria 
gonorrhoeae (MIC 
range/MIC50/MIC90 
(mg/L)) 
Phase of 
clinical trial 
(aimed size) 
Dose Comparator Adverse 
effects 
Solithromycin 
(CEM-101) 
Fluoroke
tolide 
Binds to the 50S 
ribosomal subunit, 
inhibiting protein 
synthesis 
23S rRNA 
(A2059G in 23S rRNA 
alleles, 
overexpressed 
MtrCDE increases 
MIC202,457) 
0·001-32/0·064-
0·125/0·125-
0·25202,210 
Phase 3 (300 
participants) 
1 g×1 
p.o.  
Ceftriaxone 500 
mg×1 IM PLUS 
Azithromycin 1 
g×1 p.o. 
 
Diarrhoea, 
nausea and 
fatigue/ast
heniaa 
Zoliflodacin 
(AZD0914, 
ETX0914) 
Spiropyri
midinetri
one 
DNA biosynthesis 
inhibition and 
accumulation of 
double-strand 
cleavages 
DNA gyrase and 
Topoisomerase IV? 
(D429N, D429A, and 
K450T in GyrB,197,201 
overexpressed 
MtrCDE increases 
MIC201) 
≤0·002-0·25/0·064-
0·125/0·125-
0·25206,211,215,216 
Phase 2 (180 
participants) 
2 g×1 
p.o. or 
3 g×1 
p.o.  
Ceftriaxone 500 
mg×1 IM 
Transient 
dysgeusia, 
mild 
headache 
Gepotidacin 
(GSK2140944) 
Topoiso
merase II 
inhibitor 
Inhibits DNA 
replication through 
interactions with GyrA 
(subunit of DNA 
gyrase) and ParC 
(subunit of 
Topoisomerase IV) 
DNA gyrase and 
Topoisomerase IV 
(data not available) 
 
≤0·015-
1/0·25/0·5213 
Phase 2 
(100 
participants) 
1·5 g×1 
p.o. or 
3 g×1 
p.o. 
- Data not 
available 
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aAdverse events observed in ≥10% of patients using solithromycin 1 g×1 in published Phase 2 trial. Most nausea and vomiting appeared ≥1 hour after ingestion of 
solithromycin, which indicates that the drug was already absorbed.203 
Table 1: Novel antimicrobials in different stages of clinical trial evaluation for treatment of gonorrhoea
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 Comprehensive case management: primary prevention (e.g. public health campaigns, 
sexual education, behavioural counselling, condom use), screening (where feasible, 
effective and cost-effective), early diagnosis, treatment (including test of cure); partner 
notification and treatment; reporting and epidemiological surveillance, to reduce the 
global burden of urogenital and extragenital gonorrhoea; 
 Strict adherence to international/national evidence-based prevention and management 
guidelines: including introduction of dual antimicrobial therapy where up-to-date, local, 
and high-quality AMR data do not support other therapy;  
 Enhanced focus on prevention, early diagnosis (screening of high-risk groups, e.g., men 
who have sex with men (MSM) in some settings), and appropriate treatment of pharyngeal 
gonorrhoea, which is more difficult to eradicate than anogenital gonorrhoea, mostly 
asymptomatic, and a reservoir for development of AMR;157 
 Enhanced testing and appropriate use of nucleic acid amplification tests (NAATs) but 
maintain (and strengthen in some settings) capacity for culture and AMR testing; 
 Effective drug regulations, prescription policies, and increased awareness on correct use of 
antimicrobials; 
 Monitoring, early detection and follow-up of failures with recommended treatment; using 
standard case definition and protocols for verification, management of failure and 
reporting; 
 Strengthened quality assured surveillance of gonorrhoea, antimicrobial use/misuse and 
AMR globally (including international rapid communication networks); 
 Capacity building to establish regional networks of laboratories to perform quality-assured 
gonococcal culture and AMR testing; 
 Research to identify novel antimicrobials (or other effective compounds) for treatment of 
urogenital and extragenital gonorrhoea (consider to include any new antimicrobials in a 
dual antimicrobial regimen),152,153,158,458 a gonococcal vaccine,150 rapid molecular methods 
for predicting AMR (for AMR surveillance but ideally also to inform individualized 
treatment),190-192 rapid point of care tests for diagnosis of gonorrhoea (ideally with 
combined prediction of AMR);190,191 ideal phylogenomics of gonococci and their AMR (also 
in non-cultured samples);159,457,459-464 and appropriate models for pharmacokinetics/ 
pharmacodynamics (urogenital and extragenital sites) and prediction of AMR 
induction/selection, evolution and biological fitness. 
 
Table 2: Actions to control the emergence, spread and impact of antimicrobial resistance (AMR) in 
Neisseria gonorrhoeae (public and private sectors)  
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Organism, Test Sample type Sensitivity (%) Specificity (%) 
Chlamydia trachomatisa    
Biostar OIA Chlamydia testb Endocervical swabs 59·4-73·8 98·4-100 
Clearview Chlamydial testb Endocervical swabs 49·7 97·9 
Vaginal swabs 32·8 99·2 
Quick Vue Chlamydia rapid 
testb 
Endocervical swabs 25·0-65·0 100 
Vaginal swabs 83·5 98·9 
aQcare Chlamydia TRFc Endocervical and urethral 
swabs 
93·8 96·8 
Urine 88·2 94·7 
Chlamydial Rapid Test, 
Diagnostics for the Real 
Worldc 
Male urine 41·4 89·0 
Vaginal swabs 39·4-74·2 94·4-96·8 
ACON Chlamydia Rapid Test 
Devicec 
Vaginal swabs 66·7 91·3 
Endocervical swabs 22·7-30·5 99·8-100 
Male urine 43·8 98·3 
GeneXpert CT/NGb Endocervical swabs 97·4 99·6 
Vaginal swabs 98·7 99·4 
Female urine 97·6 99·8 
Male urine 97·8 99·9 
Neisseria gonorrhoeaea    
Biostar OIA GC Testb Endocervical swabs 60·0 89·9 
Urine 100 93·0-98·0 
ACON Duo CT/NGc Endocervical swabs 12·5 99·8 
GeneXpert CT/NGb Endocervical swabs 100 100 
Vaginal swabs 100 99·9 
Female urine 95·6 99·9 
Male urine 98·9 99·9 
Trichomonas vaginalis    
OSOM TV rapid testb Vaginal swabs 83·3-90 98·8-100 
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GeneXpert TVd Vaginal swabs 95·0-95·6 95·7-100 
Affirm VPIII microbial 
identification testa,b 
Vaginal swabs 46·3 100 
Treponema pallidum 
(syphilis) 
   
Alere Determine Syphilis TPe Whole blood/serum/plasma 59·6-100 95·7-100 
Omega VisiTect Syphilise Whole blood/serum/ plasma 72·7-98·2 98·1-100 
Qualpro Syphicheck-WBe Whole blood/serum/ plasma 64-97·6 98·4-99·7 
SD Bioline Syphilis 3.0e Whole blood/ serum/plasma 85.7-100 95.5-99.4 
Span Diagnostics Crystal TP 
Syphilis Test 
Whole blood/ serum/plasma Not available Not available 
CTK Biotech OnSiteTM Syphilis 
Ab combo Rapid 
Whole blood Not available Not available 
Diagnostics Direct Syphilis 
Health CheckTM  
Whole blood/ serum/plasma Not available Not available 
Uni-GoldTM syphilis 
Treponemal  
Whole blood/ serum/plasma Not available Not available 
Dual Path Platform (DDP®) 
Syphilis Testf (Chembio 
Diagnostic Systems, Inc) 
Treponemal antibody 90·1-98·2 91·2-98·0 
Non-Treponemal 80·6-98·2 89·4 
Dual HIV/TP Syphilis    
SD Bioline HIV/Syphilis Duo 
Rapid Testg (Alere/Standard 
Diagnostics, Inc) 
Whole blood/ serum/plasma 97·9-99·0 99·0-100 
Whole blood/ serum/plasma 93·0-99·6 99·1-100 
DPP® HIV-Syphilis Assayg 
(Chembio Diagnostic Systems, 
Inc) 
Whole blood/ serum/plasma 98·9 97·9-99·6 
Whole blood/ serum/plasma 95·3 97·0-99·6 
Multiplo Rapid TP/HIV 
Antibody Testg (MedMira, Inc) 
Whole blood/ serum/plasma 97·9 94·2-99·5 
Whole blood/ serum/plasma 94·1 94·2-99·1 
INSTITM HIV/Syphilis Multiplex 
Test (Biolytical Laboratories, 
Inc) 
Whole blood/ serum/plasma Not available Not available 
Whole blood/ serum/plasma Not available Not available 
OnSiteTM HIV/Syphilis Ab 
Combo Rapid  Test (CTK 
Biotech) 
Whole blood/ serum/plasma Not available Not available 
Whole blood/ serum/plasma Not available Not available 
86 
 
a= Sensitivity and specificity compared with nucleic acid amplification tests; b= Data taken from352; c= 
Data taken from359,360; d = Data taken from353; e= Data taken from350; f=Data taken from365; g= Data 
taken from325  
Table 3: Point-of-care tests for sexually transmitted infections currently on the market with 
available sensitivities and specificities  
 
 
  
87 
 
Table 4: Call to Action  
Policy Priorities  Research Priorities  
Ensure accessible health care for early 
treatment of symptomatic STIs 
 
Develop measures of ‘access to health 
care services’ and set minimum bench 
marks 
Improve health outcomes from 
chlamydia, such as pelvic inflammatory 
disease by better case management 
 
Robust trials of strategies to increase 
chlamydia re-testing and partner 
notification and treatment 
Enhance surveillance of pelvic 
inflammatory disease, ectopic pregnancy 
and infertility  
Develop non-invasive tools to detect 
upper genital tract infection and disease 
 
Develop and implement effective partner 
treatment 
 
Robust trials of innovative partner 
treatment strategies with biological 
outcomes (e.g. reinfection rates) 
New antimicrobials and/or other 
treatments for gonorrhoea 
 
Fund research into new antimicrobials 
and treatments for gonorrhoea  
Reduce gonorrhoea prevalence  Identify key drivers of gonorrhoea 
prevalence and effective interventions to 
reduce it  
Develop treatments for bacterial 
vaginosis (BV) with low relapse rates 
 
Explore new agents that target the 
biofilm; re-evaluate the role of treatment 
of male sex partners 
Evaluate partner treatment for BV New partner treatment trials and identify 
the transmissible agent(s) responsible for 
BV 
Ensure 100% of pregnant women are 
screened and treated for syphilis at the 
first prenatal visit 
Increase implementation research to 
strengthen health systems to effectively 
identify and manage syphilis using simple 
and rapid POC tests 
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Point-of-care (POC) tests for STIs 
 
Identify the key health systems required 
for effective use of POC tests, 
Develop new POC tests for STIs, 
Evaluate the use of POC tests for STIs 
Pre-exposure prophylaxis (PrEP) and STI 
testing  
Identify the effect that frequent STI 
screening has on STI incidence  
Vaccines for STIs150  
 
Undertake the laboratory and 
subsequent clinical research necessary 
for successful vaccines  
150Footnote.  The elements of this panel assume that other elements of an effective STI control 
program are already in place including; sound sex education programme throughout school, 
strong partner notification programmes that use the latest information technology systems and 
legislative changes for partner delivered antibiotic treatment where appropriate, legalised 
frameworks for sex work, active targeted health promotion, accurate surveillance 
programmes. 
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Supplementary Table 1: Explanatory notes on hospital discharge rates presented in 
Figure 5.
122
 
Country Source Comment 
Australia Australian Institute of Health and 
Welfare Hospital Morbidity Database 
Reference period: 1 July to 30 June. 
Coverage: 
- Data are derived using AIHW analysis of the 
AIHW National Hospital Morbidity Database 
(NHMD). Please see 
http://meteor.aihw.gov.au/content/index.ph
tml/itemId/611030 for the data quality 
statement for the 2013–14 NHMD. For each 
reference year, these data are based on 
hospital separations from 1 July to 30 June. 
- Data are for principal diagnosis, recorded 
using the ICD-9-CM from 1993-94 to 1997-
98, and recording using the ICD-10-AM 
(Australian modification) from 1998-99. For 
2013-14, principal diagnoses were recorded 
using the ICD-10-AM 8th edition. 
- Data presented are based on overnight 
admitted patient separations. They exclude 
same-day separations. 
Austria Statistics Austria, Hospital discharge 
database; raw data: Austrian Ministry 
of Health 
Reference period: 31 December. 
- Coverage by hospital type: The Austrian 
hospital discharge database covers all 
inpatient institutions classifiable as HP.1 
according to SHA/OECD. 
- Missing records: The database includes all 
inpatient discharges and day cases: 
- Day cases are all cases admitted and 
discharged on the same day (before 
midnight). 
- Inpatients include discharges to home, 
other inpatient-institutions and deaths in 
hospitals. 
The Austrian hospital discharge database is 
based on the Austrian DRG system (DRG = 
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Country Source Comment 
diagnosis related group). 
Belgium The Federal Public Service of Health, 
Food Chain Safety and Environment, 
Directorate 1 -Minimal Clinical Data. 
Reference period: during the year. 
Coverage: 
- The Federal Public Service of Health, DG 1 
"Organisation of health institutions" is 
responsible for the registration of the 
Minimal Hospital Data. 
- Hospital days for inpatients concern only 
acute admissions in acute hospitals (with at 
least 1 overnight stay in the hospital). 
- Patient data in psychiatric hospitals are 
NOT included. 
- Long lasting stays are excluded (more than 
6 months or 184 days). 
- Deceased patients are included. 
Canada Statistics Canada, Hospital Morbidity 
Database, 1980/81 to 1993/94. 
- Canadian Institute for Health 
Information, Discharge Abstract 
Database and Hospital Morbidity 
Database starting in 1994/95 (the 
Hospital Morbidity Database was 
transferred from Statistics Canada to 
the Canadian Institute for Health 
Information in 1994/95), Ontario 
Mental Health Reporting System 
starting in 2006/07 until 2012/13, and 
Hospital Mental Health Database 
starting in 2013/14. 
Reference period: April 1 to March 31st 
Coverage: 
- Data are calculated on a fiscal year basis 
(April 1st to March 31st). All ten Canadian 
provinces are included for all years. In 
1994/95, one territory is included while for 
1995/96 to 2012/13 all territories are 
included, except in 2002/03 when the 
territory of Nunavut is excluded. 
- Separations in Canada include discharges 
both alive and dead for the condition most 
responsible for the length of stay. 
- Data are for acute care hospitals only, 
except for the data on mental and 
behavioural disorders which include 
psychiatric hospitals starting in 2013/14. 
- The data are reported as per ICD-9 until 
2000/01. In 2001/02, five provinces and one 
territory provided their data for the first 
time, according to ICD-10-CA; in 2002/03 two 
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Country Source Comment 
more provinces and two more territories 
reported according to ICD-10-CA. In 2003/04, 
only Manitoba and Quebec did not submit 
their data according to ICD-10-CA. In 
2004/05, Manitoba adopted the ICD-10-CA 
and Quebec did the same in 2006/07. 
- The total count of separations in provinces 
that still reported according to ICD-9, for 
each diagnostic category was added to the 
count for the provinces and territories that 
reported according to ICD-10-CA. 
Chile Ministry of Health (MINSAL), 
Department of Health Statistics and 
Information (DEIS). 
Hospital discharges from 2001-2013 
Coverage: 
- Data coverage is nationwide. Data include 
both public and private sectors. 
- Data include same-day separations and 
deaths. 
- Annual periodicity. Data are automatically 
collected monthly from the health 
establishments’ information systems and 
validated and published by the Department 
of Health Statistics and Information (DEIS). 
 
Estonia Ministry of Social Affairs, Department 
of Health Information and Analysis, 
routinely collected aggregate hospital 
statistics. 
- Since 1st January 2008: National 
Institute for Health Development, 
Department of Health Statistics 
Reference period: Calendar year. 
Coverage: 
- Coverage by hospital type: All hospitals 
(HP.1), public and private, are covered. 
- ICD-10 is used for data collection. 
- Inpatient cases: Data on discharges are 
collected in two ways: 1) Discharges 
according to ICD-10 main chapters by sex 
and age groups include deceased patients 
but not bed-days; 2) Hospital discharges by 
selected ICD-10 subgroups/single diagnoses 
and corresponding bed-days. 
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Country Source Comment 
France Ministère du Travail, de l’Emploi et de 
la Santé, Drees (Direction de la 
recherche, des études, de l'évaluation 
et des statistiques) - BESP; National 
databases from the "programme de 
médicalisation des systems 
d'information (PMSI)" (since 1997). 
Reference period: Calendar year. 
Coverage: 
- French data cover residents of 
Metropolitan France and/or overseas 
Départements (Guadeloupe, Martinique, 
French Guyana and Réunion Island but not 
Mayotte), who were hospitalised in the 
public and private hospitals of the same 
area. They refer to hospitalisations (and not 
to patients) in the units delivering acute care 
in medicine, medical specialties, surgery, 
surgical specialties, gynecology and 
obstetrics (MCO). Database contains all 
inpatient hospitalisations, including iterative 
care, and ambulatory cases except 
haemodialysis, chemotherapy, radiotherapy 
and other iterative treatments. 
 
Ireland The data presented are derived from 
the HIPE (Hospital In-Patient Enquiry) 
data set, which records data on 
discharges from all publicly funded 
acute hospitals. HIPE is operated by 
the Healthcare Pricing Office 
(www.hpo.ie). 
Reference period: Data are based on the 
year of discharge. 
Coverage: 
Coverage by hospital type 
- HIPE data covers all inpatients and day 
cases receiving curative and rehabilitative 
care in publicly funded acute hospitals in the 
State.  
Data for 1995 to 2004 were classified using 
ICD-9-CM. All HIPE discharges from 2005 are 
now coded using ICD-10-AM (The Australian 
Modification of ICD-10 incorporating the 
Australian Classification of Health 
Interventions). Although the ISHMT is used 
for categorising diagnoses, there are still 
some minor changes in the classification of 
diagnoses. The HMT shortlist is based on ICD-
9 and ICD-10 codes, but the classification 
used for diagnoses in HIPE was changed from 
ICD-9-CM to ICD-10-AM including the 
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Country Source Comment 
Australian Coding Standards.  
Slovenia National Institute of Public Health, 
Slovenia; National Hospital Health 
Care Statistics Database. 
Reference period: During the year. 
Coverage: 
- Coverage by hospital type: data include all 
private and public hospitals, all types 
(general and university - HP.1.1, 
psychiatric - HP.1.2, and specialty hospitals - 
HP.1.3). 
- Data include: 
- Inpatient discharges 
- Day-cases discharges 
- All patients (including uninsured, 
foreigners) 
- Long duration stays in hospitals 
- Palliative care in hospitals 
- Healthy newborn babies (since 2003) 
Definition of main diagnosis: the main 
diagnosis is defined as that which was 
responsible for the patient’s admission at the 
hospital, which best reflects the main reason 
for admission, or that which is the main 
reason for treatment. If there is a multiple-
episode case the main diagnosis is taken 
from the first episode. 
Switzerla
nd 
FSO Federal Statistical Office, 
Neuchâtel. Medical Statistics of 
Hospitals, 2002 and following years. 
Reference period: Annual census. 
Coverage: 
- Coverage by hospital type: The data cover 
all inpatient institutions (public and private 
hospitals) which are classifiable as HP.1 
providers. However, military and prison 
hospitals are not included. 
- Definition of main diagnosis: The main 
diagnosis is defined as the condition 
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Country Source Comment 
diagnosed at the end of the hospitalisation 
period, primarily responsible for the 
patient’s need for treatment or examination 
at the hospital. 
 
United 
Kingdom 
Data have been aggregated by the 
NHS Information Centre for Health 
and Social Care from the following 
sources: 
- England: Hospital Episode Statistics 
(HES); Inpatients, Health & Social Care 
Information Centre (HSCIC), England. 
http://www.hscic.gov.uk. 
- Wales: Patient Episode Database for 
Wales (PEDW), NHS Wales Informatics 
Service (NWIS). 
http://www.statswales.wales.gov.uk/i
ndex.htm. 
- Scotland: Information Services 
Division (ISD), National Health Service 
Scotland (SMR01 records). 
http://www.isdscotland.org/Health-
Topics/Hospital-
Care/Data_Sources_and_Clinical_Codi
ng.doc. 
- Northern Ireland: Hospital Inpatient 
System (HIS), The Department for 
Health, Social Services and Public 
Safety in Northern Ireland 
(DHSSPSNI). 
http://www.dhsspsni.gov.uk/hospital-
activity. 
Reference period: 
- England, Wales and Scotland: Data is based 
on Financial Discharge Years 1st April to 31st 
March. 
- Northern Ireland: Data have been tabled by 
calendar year. 
- Includes records for discharge dates 
occurring in the reference year, regardless of 
admission date. 
Coverage: 
- Coverage by hospital type: 
England: Inpatient data cover activity in 
English NHS Hospitals and English NHS 
commissioned activity 
in the independent sector. Scotland: Data 
collected on discharges from non-obstetric 
and non-psychiatric hospitals (SMR01) in 
Scotland. Only patients treated as inpatients 
or day cases are included. The specialty of 
geriatric long stay is 
excluded. 
Wales: All NHS commissioned data carried 
out in private sector hospitals is included. 
Northern Ireland: Inpatient data cover 
activity in Northern Ireland HSC hospitals 
including independent sector activity carried 
out in HSC hospitals. 
USA Centers for Disease Control and 
Prevention/National Center for Health 
Statistics/National Hospital Discharge 
Coverage: 
- National representative sample of the U.S. 
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Country Source Comment 
Survey Annual Summary, Advance 
Data from Vital and Health Statistics 
Summary (published annually). Vital 
and Health Statistics, Series 13, 
completed by unpublished tables. 
http://www.cdc.gov/nchs/about/maj
or/hdasd/nhds.htm. 
civilian non-institutionalised population. 
- The National Hospital Discharge Survey 
(NHDS) defines a hospital discharge as the 
formal release of an inpatient by a hospital, 
terminating of the period of hospitalisation 
(including stays of 0 nights) by death or by 
disposition to the place of residence, nursing 
home, or another hospital; survey of 
discharges from non-federal hospitals in 
which the Average Length of Stay is less than 
30 days. 
- The National Hospital Discharge Survey 
(NHDS) is a continuing nationwide sample 
survey of short-stay hospitals in the United 
States. The scope of NHDS encompasses 
patients discharged from non-institutional 
hospitals located in the 50 States and the 
District of Columbia, excluding military and 
Department of Veteran’s Affairs hospitals. 
- All U.S. discharges were coded to the 
International Classification of Diseases, Ninth 
Revision (ICD-9). 
- A hospital discharge is the completion of 
any continuous period of stay in a hospital as 
an inpatient. 
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